var title_f13_24_13696="Excision rectovaginal fistula";
var content_f13_24_13696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fistula tract is excised, including the adjacent vaginal and rectal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13696=[""].join("\n");
var outline_f13_24_13696=null;
var title_f13_24_13697="Calculator: Apgar score";
var content_f13_24_13697=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"ApgarScore_form\" name=\"ApgarScore_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Apgar score",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Strength and regularity of heart rate",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           100 beats/minute or more (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than 100 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Lung maturity",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Regular breathing (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Irregular (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Muscle tone and movement",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Active (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Limp (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Skin color / oxygenation",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Pink (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Bluish extremeties (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Totally blue (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Reflex response to irritable stimuli",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Crying (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Whimpering (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"ApgarScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Silence (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Apgar Score",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           7-10 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Normal",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-6 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Distress",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Apgar V. A proposal of a New Method of Evaluation of the Newborn Infant.",
"        <i>",
"         Current Researches in Anesthesia and Analgesia",
"        </i>",
"        . 1953, 32: 261-267.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Apgar V, Holaday DA, James LS, et. al. Evaluation of the newborn infant.",
"        <i>",
"         JAMA",
"        </i>",
"        . 1958, 168: 1985-1988.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 2001 Feb 15;344(7):467-71.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"ApgarScore_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13697=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function ApgarScore_fx() {",
"with(document.ApgarScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 2;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 0;",
"}",
"if (cc2[0].checked){",
"Score = Score + 2;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 0;",
"}",
"if (cc3[0].checked){",
"Score = Score + 2;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 0;",
"}",
"if (cc4[0].checked){",
"Score = Score + 2;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 0;",
"}",
"if (cc5[0].checked){",
"Score = Score + 2;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 0;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 7) && (Score <= 10)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 0) && (Score <= 6)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f13_24_13697=null;
var title_f13_24_13698="Hirsutism (excess hair growth in women)";
var content_f13_24_13698=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/24/13698/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13698/contributors\" id=\"au4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/24/13698/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13698/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/24/13698/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13698/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/24/13698?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIRSUTISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hirsutism refers to the growth of coarse, dark hair in areas where women typically grow fine hair or no hair at all &mdash; above the lip and on the chin, chest, abdomen, and back. This excess hair growth is caused by an increased level of male hormones (androgens). Although all women produce androgens, increased levels of androgens can lead to hirsutism.",
"    </p>",
"    <p>",
"     Women with excess hair growth need to be evaluated by a healthcare provider, especially if the hair develops or worsens rapidly, or if her relatives have comparatively less hair growth. In the vast majority of cases, hirsutism is not caused by a serious medical condition; however, the cause of hirsutism should be determined, and underlying conditions may need to be treated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HIRSUTISM CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Hirsutism is caused by an excess production or action of hormones called androgens, secreted by the ovaries or adrenal glands. Several different conditions can lead to hirsutism. The two most common causes of hirsutism are polycystic ovary syndrome (PCOS) and idiopathic hirsutism. Both are diagnosed by physical examination, medical and family history, and sometimes, blood tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Polycystic ovary syndrome (PCOS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with PCOS often have hirsutism in combination with acne, balding near the front of the head, and menstrual irregularities. PCOS is a chronic condition, but several treatments can reduce hair growth.",
"    </p>",
"    <p>",
"     PCOS is also associated with other medical problems, such as infertility (due to irregular menstrual cycles), obesity, diabetes mellitus, high cholesterol levels, and possibly heart disease. Effective treatments for PCOS are available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Idiopathic hirsutism",
"     </span>",
"     &nbsp;&mdash;&nbsp;Idiopathic hirsutism refers to hirsutism that has no identifiable cause. It is usually chronic and may be a mild variation of PCOS. A gradual increased growth of coarse body hair is typically the only symptom in women with this condition. Menstrual cycles are normal in women with idiopathic hirsutism.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HIRSUTISM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The decision to treat hirsutism is sometimes a matter of personal choice. There is a wide range of \"normal\" amounts of body hair among women. Race and ethnicity play a major role in the growth of body hair. As an example, Asian and Native American women tend to have little body hair, whereas Middle Eastern and Mediterranean women tend to have moderate to large amounts of body hair.",
"    </p>",
"    <p>",
"     Our culture also determines how much hair is cosmetically acceptable and how important it is to remove \"excessive\" hair. The psychological impact of hirsutism can range from annoying to severely disabling. Any woman who is troubled by hirsutism should not hesitate to ask her healthcare provider about treatment options.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Treatment expectations",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatment of hirsutism requires patience, because hair follicles have a life cycle of about six months. Most medications must be taken for six months before a noticeable improvement occurs. In the meantime, the existing hair can be mechanically removed or bleached, and some women continue to use these methods in combination with medication.",
"    </p>",
"    <p>",
"     Your provider will monitor the progress of treatment and may repeat tests if he or she is concerned about an underlying condition. If a medication is ineffective initially, the dose or type of medication may be changed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Duration of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hirsutism is usually treated indefinitely because, in most cases, the body continues to produce excess androgens. However, hirsutism treatments must be stopped before becoming pregnant.",
"    </p>",
"    <p>",
"     Some women eventually decide that the results of treatment are not worth the time, effort, and cost, or they grow more comfortable with their body hair.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Treatment for hair growth related to PCOS",
"     </span>",
"     &nbsp;&mdash;&nbsp;The hirsutism of PCOS and idiopathic hirsutism are treated in similar ways. The treatment of PCOS may also involve treatment of infertility, diabetes, and risk factors for cardiovascular disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Hair removal and lightening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several methods can be used to physically remove or lighten excess hair so that it less noticeable. These methods can be used in conjunction with medication. However, women with hirsutism who are trying to become pregnant or are already pregnant cannot take medications for hirsutism. Pregnant women should ask their healthcare provider about the safety of the various mechanical and chemical treatment methods during pregnancy. Electrolysis and laser are both called &ldquo;permanent hair reduction&rdquo; techniques. However, for women with PCOS, hair will grow back after either treatment, unless medication to suppress hair growth is also taken (a birth control pill or antiandrogen).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Shaving &mdash; Shaving is a safe and effective method for hair removal but may require daily sessions.",
"      </li>",
"      <li>",
"       Chemical hair removal, waxing, and bleaching &mdash; Hair removal agents and wax can be used to remove hair, and bleaches can be used to lighten hair. Depilatories and bleaches may cause skin sensitivity in some women, so be certain to follow the directions for patch testing.",
"      </li>",
"      <li>",
"       Electrolysis &mdash; Electrolysis damages individual hair follicles by inserting a very fine needle into the hair follicle and applying an electrical current. Electrolysis is best suited for treatment of small areas, although larger areas may be treated with multiple sessions over time. The treatment is safe and effective, but it can be painful and is often expensive. To find a qualified electrologist, inquire regarding the individual's training, experience, and licensing.",
"      </li>",
"      <li>",
"       Laser hair removal &mdash; Although expensive, laser hair removal is effective, faster, and less painful than electrolysis. It can often permanently reduce hair growth, particularly in those who are fair-skinned with dark hair. Most people require four to six treatments spaced approximately four to six weeks apart in order to achieve satisfactory hair removal, and maintenance treatments may be needed once every six to twelve months to remove the smaller fine hairs that grow back.",
"      </li>",
"      <li>",
"       Creams &mdash; Eflornithine hydrochloride (Vaniqua&reg;) is a skin cream that can be used to slow the growth of unwanted facial hair in women. It does not remove hair permanently. Noticeable results take about six to eight weeks, and once the cream is discontinued, hair returns to pretreatment levels after about eight weeks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight loss in overweight women can decrease levels of androgens and lessen hirsutism. Women with menstrual irregularities may also notice that their cycles become more regular after losing weight. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several medications are available for the treatment of hirsutism. These medications can decrease the amount of body hair, stop the growth of new hair, and decrease the growth rate and coarseness of existing hair. Most of these medications must be taken for at least six months before improvement is detectable, and not all medications are equally effective in all women.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Birth control pills &mdash; Birth control pills lower the levels of androgens. They are usually the first choice for the treatment of hirsutism, and between 60 and 100 percent of women with hirsutism will notice improvement when taking these medications. Birth control pills can also help establish regular menstrual cycles in women who have irregular cycles or who do not menstruate at all. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Anti-androgens &mdash; Anti-androgens are medications that directly decrease androgen production or block the action of androgens on the hair follicle. Because these medications may cause birth defects, an effective form of birth control (eg, birth control pills) is required for sexually active premenopausal women who take antiandrogens.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       The most commonly used anti-androgen is spironolactone. Spironolactone may be recommended, in addition to the birth control pill, if excess hair growth does not improve adequately after taking a birth control pill for six months. If the initial dose is not effective after several months of treatment, a higher dose may be recommended.",
"      </li>",
"      <li>",
"       Finasteride (Propecia&reg;; Proscar&reg;) is another option that is effective in some women, but it is not approved for use in women in the United States and is often not covered by insurers. Cyproterone acetate is an effective antiandrogen that is unavailable in the United States. It is used commonly in Europe and Canada, where it is a component of a birth control pill (Diane&reg;, Diane-35&reg;, Dianette&reg;).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112107203\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046386889\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=see_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=see_link\">",
"      Patient information: Sertoli-Leydig cell tumor (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046386919\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112107230\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link\">",
"      Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=see_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"      Treatment of hirsutism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=see_link\">",
"      Treatment of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32005?source=see_link\">",
"      Use of GnRH agonists in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003148.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003148.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/Resources/patientguides.cfm\">",
"      www.hormone.org/Resources/patientguides.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/24/13698/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/24/13698?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13698/abstract/1\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13698/abstract/2\">",
"      Ramos-e-Silva M, de Castro MC, Carneiro LV Jr. Hair removal. Clin Dermatol 2001; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13698/abstract/3\">",
"      Tanzi EL, Lupton JR, Alster TS. Lasers in dermatology: four decades of progress. J Am Acad Dermatol 2003; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13698/abstract/4\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_24_13698=[""].join("\n");
var outline_f13_24_13698=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIRSUTISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HIRSUTISM CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HIRSUTISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13699="Type 3 breast lobule";
var content_f13_24_13699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Type 3 breast lobule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whole mount preparation of breast tissue of a 35-year-old parous woman showing type 3 breast lobule as viewed&nbsp;by light microscopy.",
"    <br>",
"     &nbsp;",
"     <br>",
"      Left panel: tissue section stained with toluidine blue X 2.5. Right panel: histological section of lobule type 3 stained with hematoxylin and eosin (H &amp;E). Photographs at 10x (left panel) and 40x (right panel) respectively.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Russo, J, Hu, Y-F, Silva, IDCG, and Russo, IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13699=[""].join("\n");
var outline_f13_24_13699=null;
var title_f13_24_13700="Calcium glubionate: Patient drug information";
var content_f13_24_13700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium glubionate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/46/37604?source=see_link\">",
"     see \"Calcium glubionate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25045?source=see_link\">",
"     see \"Calcium glubionate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3274451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcionate [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, kidney stones, or low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after a high bran or fiber meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soft, brittle bones (osteoporosis):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11384 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-AA34A315B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13700=[""].join("\n");
var outline_f13_24_13700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3274451\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855602\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012808\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012804\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012809\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012810\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/46/37604?source=related_link\">",
"      Calcium glubionate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25045?source=related_link\">",
"      Calcium glubionate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13701="Calcium phosphate, tribasic: Pediatric drug information";
var content_f13_24_13701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium phosphate, tribasic: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/58/21412?source=see_link\">",
"    see \"Calcium phosphate, tribasic: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20596?source=see_link\">",
"    see \"Calcium phosphate, tribasic: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Posture&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1003141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1003156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/58/21412?source=see_link\">",
"      see \"Calcium phosphate, tribasic: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females 19-50 years, males 19-70 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females &ge;51 years, males &ge;71 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration: Dose expressed as",
"     <b>",
"      elemental calcium",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1-2 g or more per day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunctive prevention and treatment of osteoporosis:",
"     </b>",
"     Adults: 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     2-3 times/day; recommended dosage includes dietary intake and should be adjusted depending upon the patient&rsquo;s diet; to improve absorption do not administer more than 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Posture&reg;: Calcium 600 mg and phosphorus 280 mg [as tricalcium phosphate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3430360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1003142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of calcium deficiency; dietary supplement; adjunctive prevention and treatment of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Constipation, dry mouth, hypercalcemia, hypophosphatemia, milk-alkali syndrome, nausea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3429098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease; some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1003144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, administration of an iron-containing multivitamin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1003154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid ( unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3429122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Newborns: 7-12 mg/dL; 0-2 years: 8.8-11.2 mg/dL; 2 years to adults: 9-11 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium, ionized, whole blood: 4.4-5.4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1003155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3429100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3430361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium phosphate, tribasic = 390 mg elemental calcium = 19.3 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13701/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12958 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13701=[""].join("\n");
var outline_f13_24_13701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003141\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003156\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144745\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144733\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3430360\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003142\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144767\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429098\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429099\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003144\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298943\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144741\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003154\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429121\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429122\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003155\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429100\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3430361\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12958\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12958|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/58/21412?source=related_link\">",
"      Calcium phosphate, tribasic: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20596?source=related_link\">",
"      Calcium phosphate, tribasic: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13702="Carfilzomib: Drug information";
var content_f13_24_13702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carfilzomib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/5/15444?source=see_link\">",
"    see \"Carfilzomib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14791719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kyprolis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14641045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Proteasome Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14729214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Hydrate with 250-500 mL normal saline (or other appropriate I.V. fluid) predose (recommended) and postdose (if needed) during cycle 1 (continue in subsequent cycles if necessary). Premedicate with dexamethasone (4 mg orally or I.V.) prior to all doses in cycle 1, all doses during first dose escalation cycle, and as needed with future cycles to reduce the incidence and severity of infusion reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Multiple myeloma, relapsed/refractory:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Patients with a body surface area (BSA) &gt;2.2 m",
"     <sup>",
"      2",
"     </sup>",
"     should be dosed based upon a maximum BSA of 2.2 m",
"     <sup>",
"      2",
"     </sup>",
"     . Dose adjustments for weight changes of &le;20% are not necessary, per manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Cycle 1:",
"     </i>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on 2 consecutive days, each week for 3 weeks (days 1, 2, 8, 9, 15, and 16) of a 28-day treatment cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Cycle 2 and subsequent cycles (if cycle 1 is tolerated):",
"     </i>",
"     27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on 2 consecutive days, each week for 3 weeks (days 1, 2, 8, 9, 15, and 16) of a 28-day treatment cycle. Continue until disease progression or occurrence of unacceptable toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14729217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14729212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, results from a phase 2 trial in patients with renal impairment indicate that the pharmacokinetics and safety of carfilzomib were unchanged in this patient population; no dosage adjustment is necessary in patients with baseline dysfunction, including hemodialysis (Harvey, 2012; Niesvizky, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Dialysis clearance of carfilzomib has not been studied; per manufacturer labeling, administer postdialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14729213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied; patients with ALT or AST &ge;3 times ULN and bilirubin &ge;2 times ULN were excluded from clinical trials).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14729215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      ANC:",
"     </i>",
"     Grade 3 or 4 neutropenia: Withhold dose; continue at same dose level if fully recovered before next scheduled dose. If recovered to grade 2, reduce dose by one dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Platelets:",
"     </i>",
"     Grade 4 thrombocytopenia: Withhold dose; continue at same dose level if fully recovered before next scheduled dose. If recovered to grade 3 thrombocytopenia, reduce dose by one dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Cardiac:",
"     </i>",
"     Grade 3 or 4, new onset or worsening of congestive heart failure, decreased left ventricular function, or myocardial ischemia: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, consider restarting at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Hepatic:",
"     </i>",
"     Grade 3 or 4 elevation of bilirubin, transaminases, or other liver abnormalities: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, consider restarting at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Peripheral neuropathy:",
"     </i>",
"     Grade 3 or 4: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, restart at prior dose or at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Pulmonary toxicity",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Pulmonary hypertension: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, restart at prior dose or at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Grade 3 or 4 pulmonary complications: Withhold dose until resolved or at baseline. After resolution, consider restarting (at next scheduled treatment) at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Renal:",
"     </i>",
"     Serum creatinine &ge;2 times baseline: Withhold dose until renal function has improved to grade 1 or baseline. If renal toxicity due to carfilzomib, reduce dose at the next scheduled treatment (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated. If toxicity not due to carfilzomib, restart at previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Tumor lysis syndrome:",
"     </i>",
"     Interrupt treatment until resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Other grade 3 or 4 nonhematologic toxicities:",
"     </i>",
"     Withhold dose until resolved or at baseline. After resolution, consider restarting (at next scheduled treatment) at a reduced dose level (from 27 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Consider escalating to the previous dose if reduced dose is tolerated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14729234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kyprolis&trade;: 60 mg [contains cyclodextrin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14729167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14729226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer over 2-10 minutes. Flush line before and after carfilzomib with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14729202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W. Do not mix with or administer as an infusion with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14641319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of multiple myeloma in patients who have received at least 2 prior treatment regimens (including a proteasome inhibitor and an immunomodulator) with disease progression within 60 days after the most recent treatment",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14729165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Carfilzomib may be confused with bortezomib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14729177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (24%), hypertension (14%), chest wall pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (56%), fever (30%), headache (28%), insomnia (18%), chills (16%), dizziness (13%), hypoesthesia (12%), pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (14%), hypomagnesemia (14%), hyperglycemia (12%), hypercalcemia (11%), hypophosphatemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (45%), diarrhea (33%), vomiting (22%), constipation (21%), anorexia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (47%; grade 3: 21%; grade 4: 1%), thrombocytopenia (36%; grade 3: 13%; grade 4: 10%), lymphopenia (24%; grade 3: 16%; grade 4: 2%), neutropenia (21%; grade 3: 10%; grade 4: 1%), leukopenia (14%; grade 3: 5%; grade 4:&lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (13%; grade 3: 3%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (20%), arthralgia (16%), muscle spasms (14%), peripheral neuropathy (14%; grade 3: 1%), weakness (14%), limb pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (24%; grade 3: 3%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (35%; grade 3: 5%; grade 4: &lt;1%), upper respiratory tract infection (28%), cough (26%), pneumonia (13%; grade 3: 10%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Cardiac failure (7%; includes CHF, pulmonary edema, ejection fraction decrease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyponatremia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal failure (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary arterial hypertension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes zoster reactivation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bilirubin increased, hepatic failure, infusion reaction, intracranial hemorrhage, multiorgan failure, myocardial ischemia, neutropenic fever, sepsis, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14729173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14729174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Bone marrow suppression: Thrombocytopenia (including grade 4) was observed in patients receiving carfilzomib, with platelet nadirs occurring around day 8 of each 28-day treatment cycle, and recovery to baseline by the start of the next cycle. Monitor platelets closely and adjust dose or withhold therapy if necessary. Anemia, lymphopenia, and neutropenia were also observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Cardiovascular effects: Death caused by cardiac arrest has occurred within 24 hours of administration. Carfilzomib has been associated with the development or worsening of congestive heart failure (HF) and decreased left ventricular ejection fraction (LVEF). HF, pulmonary edema, and decreased LVEF were observed in clinical trials; monitor closely for cardiac complications; withhold therapy for grade 3 or 4 cardiac events until recovery. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction (within 6 months), and conduction abnormalities not managed by medication were excluded from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Hepatic effects: Hepatic failure, including fatal cases, has been reported rarely. Increased transaminases and hyperbilirubinemia have also been observed. Interrupt therapy with grade 3 or higher hepatic toxicity until resolved or recovered to baseline; monitor liver enzymes closely and for signs of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Infusion reactions: May occur immediately following or within 24 hours of carfilzomib infusion. Symptoms have included fever, chills, arthralgia, flushing, facial edema, vomiting, weakness, dyspnea, syncope, chest tightness, or angina. To lessen the incidence and intensity of infusion reactions, administer dexamethasone prior to drug administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Pulmonary toxicities: In clinical trials, pulmonary arterial hypertension (PAH) was observed (including grade 3); perform cardiac imaging or other testing as appropriate, and withhold carfilzomib until PAH is resolved or returns to baseline. Dyspnea (including 1 death) has been reported; monitor closely, and withhold carfilzomib until symptom resolution or return to baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Tumor lysis syndrome: Risk is increased in multiple myeloma patients with a high tumor burden. Adequately hydrate patients prior to carfilzomib therapy and monitor closely for signs and symptoms of tumor lysis syndrome (TLS). If TLS occurs, interrupt treatment until resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14878017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14878015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14729169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14729170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies at doses less than the recommended human dose (based on BSA). Based on the mechanism of action, adverse fetal events would be expected to occur with use in pregnant women. Females of reproductive potential are advised to avoid pregnancy during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14729171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14729172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in nursing infants, the manufacturer recommends avoiding breast-feeding during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Kyprolis Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (1): $1989.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14729229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (monitor frequently throughout therapy); renal function, pulmonary function (with new or worsening pulmonary symptoms), liver function tests, serum creatinine. Signs/symptoms of infusion-related reactions, congestive heart failure, tumor lysis syndrome, and peripheral neuropathy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14729203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carfilzomib inhibits proteasomes, which are responsible for intracellular protein homeostasis. Specifically, it is a potent, selective, and irreversible inhibitor of chymotrypsin-like activity of the 20S proteasome, leading to cell cycle arrest and apoptosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14729205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 28 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Rapid and extensive; peptidase cleavage and epoxide hydrolysis; minimal metabolism through cytochrome P450-mediated mechanisms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Doses &ge;15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : &lt;1 hour on day 1 of cycle 1",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alsina M, Trudel S, Furman RR, et al, &ldquo;A Phase 1 Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma or Lymphoma,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012,18(17):4830-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/22761464/pubmed\" id=\"22761464\" target=\"_blank\">",
"        22761464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harvey RD, Lonial S, Patel P, et al, &ldquo;Summary of Treatment-Emergent Renal Events From Patients Treated With Single-Agent Carfilzomib From Four Phase II Studies in Relapsed and/or Refractory Multiple Myeloma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15S):e18569 [abstract e18569 from ASCO 2012 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan ML and Stewart AK, &ldquo;Carfilzomib: A Novel Second-Generation Proteasome Inhibitor,&rdquo;",
"      <i>",
"       Future Oncol",
"      </i>",
"      , 2011, 7(5):607-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/21568676/pubmed\" id=\"21568676\" target=\"_blank\">",
"        21568676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niesvizky R, Vij R, Martin T, et al, &ldquo;Carfilzomib Pharmacokinetics, Safety, and Activity in Patients With Relapsed or Refractory Multiple Myeloma and Renal Dysfunction,&rdquo;",
"      <i>",
"       Haematol",
"      </i>",
"      , 2011, 96(s2):370 [abstract 0890 from EHA 2011 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor OA, Stewart AK, Vallone M, et al, &ldquo;A Phase 1 Dose Escalation Study of The Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients With Hematologic Malignancies,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(22):7085-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/19903785/pubmed\" id=\"19903785\" target=\"_blank\">",
"        19903785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parlati F, Lee SJ, Aujay M, et al, &ldquo;Carfilzomib Can Induce Tumor Cell Death Through Selective Inhibition of the Chymotrypsin-Like Activity of the Proteasome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(16):3439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/19671918/pubmed\" id=\"19671918\" target=\"_blank\">",
"        19671918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siegel DS, Martin T, Wang M, et al, &ldquo;A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients With Relapsed and Refractory Multiple Myeloma,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 120(14):2817-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/22833546/pubmed\" id=\"22833546\" target=\"_blank\">",
"        22833546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vij R, Wang M, Kaufman JL, et al, &ldquo;An Open-Label, Single-Arm, Phase 2 (PX-171-004) Study of Single-Agent Carfilzomib in Bortezomib-Naive Patients With Relapsed and/or Refractory Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(24):5661-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/22555973/pubmed\" id=\"22555973\" target=\"_blank\">",
"        22555973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zangari M, Aujay M, Zhan F, et al, &ldquo;Alkaline Phosphatase Variation During Carfilzomib Treatment is Associated With Best Response in Multiple Myeloma Patients,\"",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2011, 86(6):484-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/24/13702/abstract-text/21477075/pubmed\" id=\"21477075\" target=\"_blank\">",
"        21477075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86042 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13702=[""].join("\n");
var outline_f13_24_13702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14791719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14641045\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729214\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729217\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729212\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729213\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729215\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729234\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729167\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729226\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729202\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14641319\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729165\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729177\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729174\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878017\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878015\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729169\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729171\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729172\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570445\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729229\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729203\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14729205\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/5/15444?source=related_link\">",
"      Carfilzomib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13703="Acute lobular hepatitis high serum bilirubin - low power";
var content_f13_24_13703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis in a 62-year-old woman with an unusually high serum bilirubin level, 55 mg/dL (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are numerous mononuclear inflammatory cells scattered throughout the parenchyma and many areas of focal liver cell necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13703=[""].join("\n");
var outline_f13_24_13703=null;
var title_f13_24_13704="Skull fractures in children";
var content_f13_24_13704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skull fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13704/contributors\">",
"     Alison Chantal Caviness, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13704/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13704/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/24/13704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures result from direct impact to the calvarium and are important because of their association with intracranial injury, the leading cause of traumatic death in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Every year, more than 600,000 children visit emergency departments in the United States for blunt head trauma; approximately 95,000 of them have intracranial injuries, and 5700 die as a result of those injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The morbidity and mortality from head injuries is increased when associated extracranial injuries are present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, complications, and management of skull fractures are reviewed here. Closed head injury and nonaccidental head trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link\">",
"     \"Minor head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of skull fractures in children who present for outpatient evaluation of head trauma ranges from 2 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"     8",
"    </a>",
"    ]. The parietal bone is involved most frequently, followed by the occipital, frontal, and temporal bones. Linear fractures are most common, followed by depressed and basilar fractures.",
"   </p>",
"   <p>",
"    The causes of skull fracture and the causes of head injury typically are not separated in the literature except for infants, who are at increased risk of skull fractures from minor mechanisms of trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The major causes of head injuries in children are [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Falls &ndash; 35 percent",
"     </li>",
"     <li>",
"      Recreational activities &ndash; 29 percent",
"     </li>",
"     <li>",
"      Motor vehicle crashes &ndash; 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Falls are a common cause of head injury in children younger than two years of age, whereas motor vehicle crashes and assault are more common in 4- to 14-year-olds [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=see_link&amp;anchor=H1#H1\">",
"     \"Prevention of falls in children\", section on 'Epidemiology'",
"    </a>",
"    .) Boys are more likely to sustain traumatic head injuries than are girls.",
"   </p>",
"   <p>",
"    Intentional injury is an important cause of skull fractures, particularly in young children. One retrospective study reviewed the medical records of 287 children (aged one week to 6.5 years) who were admitted to a metropolitan children's hospital with head injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/14\">",
"     14",
"    </a>",
"    ]. Intentional injuries accounted for 19 percent. The mean age was 0.7 years for the intentional injury group versus 2.5 years for the unintentional group. Subdural hematoma; subarachnoid hemorrhage; retinal hemorrhages; and associated cutaneous, skeletal, and visceral injuries are more common in intentional than unintentional head injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location and pattern of a skull fracture depend upon the nature and site of the causative impact. Fractures may involve the flat bones (eg, frontal, temporal, parietal, occipital) or the base of the skull. Fractures are classified according to their appearance, location, degree of depression, and whether they are in communication with lacerations or the upper respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Linear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear fractures account for approximately 75 percent of skull fractures in children. They are single fracture lines that involve the thickness of the skull and may disrupt underlying vascular structures. They start at the point of maximum impact and spread, but do not cross suture lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Comminuted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comminuted skull fractures consist of multiple associated linear fractures. They usually result from larger forces of impact than do single linear fractures. Stellate or comminuted fractures of the occipital bone often result from repeated blows against an object, and may suggest child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Depressed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressed skull fractures are the result of significant force and frequently are associated with underlying cerebral injury. They may result from blows over small areas (eg, from a hammer or heel of a shoe). The depressed bone can lacerate the underlying dura or penetrate the brain tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/15\">",
"     15",
"    </a>",
"    ]. Depressed skull fractures increase the likelihood of posttraumatic seizures and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Open",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open skull fractures are skull fractures that permit communication between the skull and the scalp or mucosal surfaces of the upper respiratory tract. Open fractures increase the risk of central nervous system (CNS) infection. The two types of open skull fractures are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skull fractures that have an overlying laceration, also called compound fractures.",
"     </li>",
"     <li>",
"      Skull fractures that disrupt the paranasal sinuses or middle ear and may be associated with CSF rhinorrhea or otorrhea. The evaluation of suspected CSF rhinorrhea is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=see_link\">",
"       \"Nasal trauma and fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a skull fracture usually is suggested by the history and physical examination. The history may include penetrating trauma, intentional injury, or injury associated with loss of consciousness. The older child may complain of localized pain and swelling. The physical examination can include soft-tissue swelling, hematoma, palpable fracture or skull defect, crepitus, or signs of basilar skull fracture. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Basilar skull fracture'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Linear skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear fractures occur most frequently in the parietal bone but can occur in any bone of the calvarium. Of linear skull fractures, 15 to 30 percent are associated with intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"     8",
"    </a>",
"    ]. Most linear skull fractures have associated physical examination findings, including overlying hematoma or soft tissue swelling; the soft-tissue swelling may not be present immediately after the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scalp hematomas are predictive of skull fractures in infants younger than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/1,9,16\">",
"     1,9,16",
"    </a>",
"    ]. In one prospective study of 422 asymptomatic infants with head injury, hematomas of the parietal or temporal regions increased the likelihood of underlying skull fracture, whereas hematomas of the frontal region did not (odds ratio: 38,16, and 0.6 for parietal, temporal, and frontal hematoma, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, a stepwise relationship was noted between the size of the hematoma and the likelihood of skull fracture (odds ratio 27, 5.5, and 3, for large, moderate, and small hematomas, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most linear skull fractures heal without complication. Rare complications include formation of subgaleal or epidural hematoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formation of subgaleal hematoma is the most common complication of linear skull fractures. Subgaleal hematomas cause localized swelling that may be extensive enough to cause anemia. They usually absorb without intervention.",
"     </li>",
"     <li>",
"      Formation of epidural hematomas is another complication of linear skull fractures. Fractures of the temporal bone that involve the middle meningeal artery may cause epidural hematomas of the temporoparietal region. Fractures of the occipital bone that involve a venous sinus may cause epidural hematomas of the posterior fossa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Depressed skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bony defects or \"step-offs\" may be palpable in children with significantly depressed skull fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 30 percent of children with depressed skull fractures have associated intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. The risks of dural tear and brain laceration increase with the depth of the depression. In addition to intracranial hemorrhage, complications of depressed skull fractures include compression of underlying brain parenchyma, intraparenchymal bone fragments, and cosmetic deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Basilar skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basilar skull fractures involve the base of the skull. Distinct clinical findings are present in approximately 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/20\">",
"     20",
"    </a>",
"    ]. The signs and symptoms of basilar skull fractures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous bleeding over the mastoid process (Battle sign)",
"     </li>",
"     <li>",
"      Subcutaneous bleeding around the orbit (raccoon eyes) (",
"      <a class=\"graphic graphic_picture graphicRef69662 \" href=\"UTD.htm?15/54/16237\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blood behind the tympanic membrane (hemotympanum) (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebrospinal fluid leak from the nose (CSF rhinorrhea)",
"     </li>",
"     <li>",
"      Cerebrospinal fluid leak from the ear (CSF otorrhea)",
"     </li>",
"     <li>",
"      Cranial nerve deficits leading to facial paralysis, anosmia, nausea, vomiting, vertigo, nystagmus, tinnitus, or hearing loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of basilar skull fractures include hearing loss, cranial nerve impairment, and CSF leakage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss occurs in up to one-half of children with basilar skull fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/21\">",
"       21",
"      </a>",
"      ]. The hearing loss may be conductive or sensorineural. Conductive hearing loss is caused by perforation of the tympanic membrane, blood in the middle ear space, or ossicular injury; sensorineural hearing loss is caused by injury to the cochlear organ of Corti. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link&amp;anchor=H13#H13\">",
"       \"Etiology of hearing impairment in children\", section on 'Trauma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cranial nerve impairment (typically nerves VI, VII, and VIII) is reported in up to 23 percent of children with basilar skull fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. In one series of 73 children, approximately one-half of the impairments resolved completely and one-half of the children had residual deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=see_link\">",
"       \"Sixth cranial nerve (abducens nerve) palsy in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=see_link\">",
"       \"Facial nerve palsy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Basilar skull fractures with underlying dural tears are associated with CSF leaks and increased risk for intracranial infection. Most CSF leaks resolve spontaneously within one week of injury. In retrospective studies, the incidence of meningitis after basilar skull fracture ranges from 0.7 to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. No prospective studies have evaluated the risk of CNS infection, nor the time of onset of infection in patients with documented CSF leakage; however, meningitis is reported to occur months to years after injury [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/24\">",
"       24",
"      </a>",
"      ]. The most common organisms are Streptococcus pneumoniae, group A beta-hemolytic streptococci, and Haemophilus influenzae [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Growing skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures associated with an underlying dural tear may fail to heal properly. Enlargement is caused by herniated brain, leptomeningeal cyst, or dilated ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/26\">",
"     26",
"    </a>",
"    ]. These fractures commonly are called growing skull fractures, traumatic encephaloceles, leptomeningeal cysts, posttraumatic porencephaly, or cephalhydroceles. Neurologic findings or cranial growth asymmetry may be present if associated compression of the underlying brain is present.",
"   </p>",
"   <p>",
"    The incidence of growing fractures is not known. In one study of 592 children with head injuries, the prevalence was 1.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/27\">",
"     27",
"    </a>",
"    ]. Growing skull fractures occur predominantly in children who are younger than three years of age and in whom the diastasis is greater than 3 to 4 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. They usually are detected within one year of an acute head injury as a localized swelling or scalp defect that increases in size [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. However, they may go undetected for years and present with delayed onset of neurologic symptoms (headache, seizure, or neurologic deficit) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8,32,33\">",
"     8,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with head trauma who are at risk for intracranial injury should be initially imaged with computed tomography (CT). Head CT identifies essentially all children with intracranial injuries requiring acute intervention. Plain radiography is of little or no added value if a head CT is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H20#H20\">",
"     \"Minor head trauma in infants and children\", section on 'Indications for neuroimaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skull radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull radiographs can be used to identify and classify skull fractures. However, the absence of a fracture does not reliably exclude intracranial injury. This was illustrated in a meta-analysis of sixteen studies to evaluate variables that predict significant intracranial injury in children with minor head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/34\">",
"     34",
"    </a>",
"    ]. Although presence of a skull fracture was a good predictor of intracranial injury, with a relative risk of 6.1 (95% CI 3.4-11.2), it was neither sensitive (59 percent) nor specific (88 percent) enough to perform well as a diagnostic test. Thus, plain radiographs should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a screening test to determine whether a child with known head trauma should undergo CT.",
"   </p>",
"   <p>",
"    Skull radiographs may be indicated when the history of trauma is uncertain (eg, skeletal survey in the evaluation of suspected abuse), or to rule out the presence of a superficial foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/35\">",
"     35",
"    </a>",
"    ]. Children who have any fracture on skull radiographs should undergo CT. Fractures that are depressed, open, or cross the middle meningeal artery groove are particularly concerning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unenhanced CT is the diagnostic method of choice for detecting intracranial injury. It is preferred over simple radiography because it can identify both skull fractures and intracranial injury; it is also more readily available and less expensive than MRI. CT should be performed in all children with a known skull fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to neuroimaging in children\", section on 'CT applications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical criteria for determining which children with minor head injury should undergo head CT is discussed separately. The threshold for obtaining a CT scan in infants younger than two years, particularly those younger than three months, should be lower than it is for older children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H20#H20\">",
"     \"Minor head trauma in infants and children\", section on 'Indications for neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound may become a useful screening tool for detecting dural tears and other findings that are associated with growing skull fractures (eg, the abnormal pulsations of herniated brain or CSF in the fracture diastasis) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/29\">",
"     29",
"    </a>",
"    ]. However, prospective data are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with a head injury is the same as that for the acutely injured child. Oral intubation is preferred to nasal intubation if intubation is indicated to avoid the disruption of a potentially fractured cribriform plate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who have depressed, basilar, or widely diastatic skull fractures should be managed in consultation with a neurosurgeon. Most of these children will require admission to the hospital for observation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"     8",
"    </a>",
"    ]. Hospital admission also should be considered for children with persistent neurologic deficits, significant extracranial injuries, persistent vomiting, suspected intentional injury, or parents who are unreliable or unable to return if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Isolated skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of CT evidence of intracranial injury, the presence of an isolated, nondepressed skull fracture with margins separated by less than 3 mm does not warrant further intervention or admission to the hospital. Observational studies suggest that the incidence of clinical deterioration or need for neurosurgical intervention in children with isolated skull fractures is low:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 235 previously healthy children (median age 11 months) with isolated skull fractures predominantly in the parietal or occipital region, no patient required neurosurgical intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/37\">",
"       37",
"      </a>",
"      ]. None of the 58 patients discharged from the emergency department after a brief period of observation (median three hours) returned for further care. The median length of stay for the 177 admitted patients was 18 hours. Five of these patients returned after discharge because of persistence symptoms. One admitted patient had delayed onset of an extraaxial intracranial hemorrhage. &nbsp;",
"     </li>",
"     <li>",
"      A prospective study of pediatric patients (average 1.8 years of age) demonstrated no clinical complications for the 44 patients admitted with isolated skull fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 101 patients younger than the age of two years with isolated skull fractures demonstrated that none had a decline in clinical status during hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Healthy children, who have normal head CT scans and no concerning symptoms, may be discharged when their mental status has normalized; they are able to tolerate liquids without vomiting, and extracranial injuries have been appropriately treated.",
"   </p>",
"   <p>",
"    Discharge criteria for children with isolated skull fractures include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No significant extracranial injuries",
"     </li>",
"     <li>",
"      No indications of intracranial injury (eg, unremitting vomiting)",
"     </li>",
"     <li>",
"      Normal neurologic examination, including ability to alert easily",
"     </li>",
"     <li>",
"      No concern for abusive head trauma",
"     </li>",
"     <li>",
"      Residence in close proximity to the hospital and reliable caretakers who are able to return the child if necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discharge instructions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keep the child at home for the first 24 hours after injury.",
"     </li>",
"     <li>",
"      Do not permit the child to ride a bike or skateboard or drive a motorized vehicle during the first 24 hours.",
"     </li>",
"     <li>",
"      Wake the child every two hours during the first night and during naps to ensure that he or she awakens as usual.",
"     </li>",
"     <li>",
"      Call immediately if the child does not awaken as usual; seems sleepy at unusual times; or has a seizure, persistent vomiting, difficulty with coordination, confusion, or a change in vision.",
"     </li>",
"     <li>",
"      The child can return to regular activities after 24 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants and young children under two years of age who have isolated skull fractures should be evaluated for growing skull fracture one to two months after the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"     8",
"    </a>",
"    ]. Fractures that have healed are not palpable, whereas unhealed fractures are palpable as a localized, often pulsatile swelling, or a scalp defect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/26,40\">",
"     26,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Open skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antibiotics typically is recommended to prevent osteomyelitis in patients with open fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with skull fractures and overlying lacerations should receive antistaphylococcal antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Basilar skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have basilar skull fractures should be managed in consultation with a neurosurgeon and, in children with middle ear effusion or otorrhea, an otolaryngologist.",
"   </p>",
"   <p>",
"    Prophylactic antibiotics are not recommended routinely for children with basilar skull fractures after nonpenetrating head trauma, even when they have CSF leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/25\">",
"     25",
"    </a>",
"    ]. No prospective, randomized, controlled trials evaluate the use of prophylactic antibiotics after basilar skull fracture, and retrospective case series do not support their routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational evidence does suggest that the risk of meningitis is significantly increased in patients with a CSF leak, especially those patients whose drainage lasts longer than seven days. In a case series of 122 patients, most of whom had otorrhea, the risk of meningitis was 3 percent among patients who experienced spontaneous resolution of the leak within seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/43\">",
"     43",
"    </a>",
"    ]. The frequency of meningitis increased to 22 percent in patients with CSF leakage beyond seven days. Prophylactic antibiotics did not appear to prevent meningitis unless obvious local infection was present. However, an adequate course of antibiotics was administered in only 22 percent of patients in this case series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If otorrhea or middle ear effusion has not resolved within seven days, additional measures are determined by the otolaryngologist, often in cooperation with a neurosurgeon, and may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lumbar drain to stop the leak by reducing intrathecal pressure",
"     </li>",
"     <li>",
"      Localization of the fistula (eg, nuclear medicine imaging or intraoperative intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      dye study) and operative repair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical intervention may be indicated sooner if a temporal bone fracture has caused entrapment of the facial nerve or disruption of the ossicles. However, most surgical intervention, if necessary for basilar skull fractures, can be delayed until cerebral perfusion pressure is stable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with basilar skull fractures and CSF leakage should receive the pneumococcal vaccine because they are at high risk for pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Depressed skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with depressed skull fractures should be managed in consultation with a neurosurgeon to determine the need for surgical elevation of the depressed fragment. Greater depression is associated with higher risk of dural tear, cortical laceration, and a worse prognosis. However, elevation may not decrease neurologic deficits, seizures, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/18,19,46\">",
"     18,19,46",
"    </a>",
"    ]. Thus, a nonoperative approach is recommended for children who have simple depressed skull fractures without associated intracranial hematoma and in whom the bone depression is less than 1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/18,19,46\">",
"     18,19,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depressed skull fractures increase the risk for posttraumatic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/47\">",
"     47",
"    </a>",
"    ]. The use of prophylactic neuroleptics is controversial. Patients with Glasgow Coma Scores of 3 to 8 (",
"    <a class=\"graphic graphic_table graphicRef81854 graphicRef78293 \" href=\"UTD.htm?28/36/29261\">",
"     table 1A-B",
"    </a>",
"    ) may benefit from prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/48\">",
"     48",
"    </a>",
"    ]. However, no evidence from controlled trials exists to support the routine use of neuroleptics in all children with depressed skull fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Growing skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing skull fractures may require surgical intervention to close the underlying dura [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/31\">",
"     31",
"    </a>",
"    ]. The management of growing skull fractures is not well studied; most evidence comes from case reports or case series. Delayed closure may lead to neurologic deficits, cranial defects, or vascular anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13704/abstract/32,49\">",
"     32,49",
"    </a>",
"    ]. Children with growing skull fractures are best managed by a neurosurgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=see_link\">",
"       \"Patient information: Skull and facial fractures (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a skull fracture usually is suggested by the history and physical examination. The history may include penetrating trauma, intentional injury, or injury associated with loss of consciousness. The older child may complain of localized pain and swelling. The physical examination can include soft-tissue swelling, hematoma, palpable fracture or skull defect, crepitus, or signs of basilar skull fracture (eg, Battle sign, hemotympanum, CSF rhinorrhea or otorrhea). Most pediatric skull fractures are linear. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unenhanced CT is the diagnostic method of choice for detecting intracranial injury. It is preferred over simple radiography because it can identify both skull fractures and intracranial injury; it is also more readily available and less expensive than MRI. Skull radiographs may be indicated when the history of trauma is uncertain (eg, skeletal survey in the evaluation of suspected abuse), or to rule out the presence of a superficial foreign body. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Computed tomography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Skull radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical criteria for determining which children with minor head injury should undergo head CT is discussed separately. The threshold for obtaining a CT scan in infants younger than two years, particularly those younger than three months, should be lower than it is for older children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H20#H20\">",
"       \"Minor head trauma in infants and children\", section on 'Indications for neuroimaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with depressed or basilar skull fractures should be managed with neurosurgical consultation. Those with an abnormal CT scan also require prompt neurosurgical evaluation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with intracranial injuries should be admitted to the hospital. In addition, admission should be considered for children with persistent neurologic deficits, significant extracranial injuries, persistent vomiting, suspected intentional injury, or parents who are unreliable or unable to return if necessary. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with isolated linear skull fractures can be discharged home after an outpatient evaluation. Discharge criteria include (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Isolated skull fractures'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No significant extracranial injuries",
"     </li>",
"     <li>",
"      No indications of intracranial injury (eg, unremitting vomiting)",
"     </li>",
"     <li>",
"      Normal neurologic examination, including ability to alert easily",
"     </li>",
"     <li>",
"      No concern for abusive head trauma",
"     </li>",
"     <li>",
"      Residence in close proximity to the hospital and reliable caretakers who are able to return with the child if necessary",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/1\">",
"      Quayle KS, Jaffe DM, Kuppermann N, et al. Diagnostic testing for acute head injury in children: when are head computed tomography and skull radiographs indicated? Pediatrics 1997; 99:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/2\">",
"      Shane SA, Fuchs SM. Skull fractures in infants and predictors of associated intracranial injury. Pediatr Emerg Care 1997; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/3\">",
"      Cheung DS, Kharasch M. Evaluation of the patient with closed head trauma: an evidence based approach. Emerg Med Clin North Am 1999; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/4\">",
"      Childhood injuries in the United States. Division of Injury Control, Center for Environmental Health and Injury Control, Centers for Disease Control. Am J Dis Child 1990; 144:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/5\">",
"      Kraus JF, Rock A, Hemyari P. Brain injuries among infants, children, adolescents, and young adults. Am J Dis Child 1990; 144:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/6\">",
"      Sanchez JI, Paidas CN. Childhood trauma. Now and in the new millennium. Surg Clin North Am 1999; 79:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/7\">",
"      Tepas JJ 3rd, DiScala C, Ramenofsky ML, Barlow B. Mortality and head injury: the pediatric perspective. J Pediatr Surg 1990; 25:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/8\">",
"      Schutzman SA, Greenes DS. Pediatric minor head trauma. Ann Emerg Med 2001; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/9\">",
"      Greenes DS, Schutzman SA. Infants with isolated skull fracture: what are their clinical characteristics, and do they require hospitalization? Ann Emerg Med 1997; 30:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/10\">",
"      Duhaime AC, Alario AJ, Lewander WJ, et al. Head injury in very young children: mechanisms, injury types, and ophthalmologic findings in 100 hospitalized patients younger than 2 years of age. Pediatrics 1992; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/11\">",
"      Ros SP, Cetta F. Are skull radiographs useful in the evaluation of asymptomatic infants following minor head injury? Pediatr Emerg Care 1992; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/12\">",
"      Kraus JF, Fife D, Cox P, et al. Incidence, severity, and external causes of pediatric brain injury. Am J Dis Child 1986; 140:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/13\">",
"      Gallagher SS, Finison K, Guyer B, Goodenough S. The incidence of injuries among 87,000 Massachusetts children and adolescents: results of the 1980-81 Statewide Childhood Injury Prevention Program Surveillance System. Am J Public Health 1984; 74:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/14\">",
"      Reece RM, Sege R. Childhood head injuries: accidental or inflicted? Arch Pediatr Adolesc Med 2000; 154:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/15\">",
"      Olshaker JS, Whye DW Jr. Head trauma. Emerg Med Clin North Am 1993; 11:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/16\">",
"      Kleinman PK, Spevak MR. Soft tissue swelling and acute skull fractures. J Pediatr 1992; 121:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/17\">",
"      Greenes DS, Schutzman SA. Clinical significance of scalp abnormalities in asymptomatic head-injured infants. Pediatr Emerg Care 2001; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/18\">",
"      Erahin Y, Mutluer S, Mirzai H, Palali I. Pediatric depressed skull fractures: analysis of 530 cases. Childs Nerv Syst 1996; 12:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/19\">",
"      Steinbok P, Flodmark O, Martens D, Germann ET. Management of simple depressed skull fractures in children. J Neurosurg 1987; 66:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/20\">",
"      Kadish HA, Schunk JE. Pediatric basilar skull fracture: do children with normal neurologic findings and no intracranial injury require hospitalization? Ann Emerg Med 1995; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/21\">",
"      Liu-Shindo M, Hawkins DB. Basilar skull fractures in children. Int J Pediatr Otorhinolaryngol 1989; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/22\">",
"      Kitchens JL, Groff DB, Nagaraj HS, Fallat ME. Basilar skull fractures in childhood with cranial nerve involvement. J Pediatr Surg 1991; 26:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/23\">",
"      Baltas I, Tsoulfa S, Sakellariou P, et al. Posttraumatic meningitis: bacteriology, hydrocephalus, and outcome. Neurosurgery 1994; 35:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/24\">",
"      Eljamel MS, Foy PM. Acute traumatic CSF fistulae: the risk of intracranial infection. Br J Neurosurg 1990; 4:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/25\">",
"      ASHP Therapeutic Guidelines for Nonsurgical Antimicrobial Prophylaxis. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1999; 56:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/26\">",
"      Jamjoom Z, Jamjoom A, Murshid WR. Growing skull fractures: classification and management. Br J Neurosurg 1994; 8:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/27\">",
"      Rinehart GC, Pittman T. Growing skull fractures: strategies for repair and reconstruction. J Craniofac Surg 1998; 9:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/28\">",
"      Gupta SK, Reddy NM, Khosla VK, et al. Growing skull fractures: a clinical study of 41 patients. Acta Neurochir (Wien) 1997; 139:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/29\">",
"      D&eacute;carie JC, Mercier C. The role of ultrasonography in imaging of paediatric head trauma. Childs Nerv Syst 1999; 15:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/30\">",
"      Thompson JB, Mason TH, Haines GL, Cassidy RJ. Surgical management of diastatic linear skull fractures in infants. J Neurosurg 1973; 39:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/31\">",
"      Muhonen MG, Piper JG, Menezes AH. Pathogenesis and treatment of growing skull fractures. Surg Neurol 1995; 43:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/32\">",
"      Kutlay M, Demircan N, Akin ON, Basekim C. Untreated growing cranial fractures detected in late stage. Neurosurgery 1998; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/33\">",
"      Vignes JR, Jeelani NU, Jeelani A, et al. Growing skull fracture after minor closed-head injury. J Pediatr 2007; 151:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/34\">",
"      Dunning J, Batchelor J, Stratford-Smith P, et al. A meta-analysis of variables that predict significant intracranial injury in minor head trauma. Arch Dis Child 2004; 89:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/35\">",
"      Frush DP, O'Hara SM, Kliewer MA. Pediatric imaging perspective: acute head trauma--Is skull radiography useful? J Pediatr 1998; 132:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/36\">",
"      Chesnut RM. The management of severe traumatic brain injury. Emerg Med Clin North Am 1997; 15:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/37\">",
"      Rollins MD, Barnhart DC, Greenberg RA, et al. Neurologically intact children with an isolated skull fracture may be safely discharged after brief observation. J Pediatr Surg 2011; 46:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/38\">",
"      Vogelbaum MA, Kaufman BA, Park TS, Winthrop AL. Management of uncomplicated skull fractures in children: is hospital admission necessary? Pediatr Neurosurg 1998; 29:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/39\">",
"      Schutzman SA, Barnes P, Duhaime AC, et al. Evaluation and management of children younger than two years old with apparently minor head trauma: proposed guidelines. Pediatrics 2001; 107:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/40\">",
"      Johnson DL, Helman T. Enlarging skull fractures in children. Childs Nerv Syst 1995; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/41\">",
"      Rabinowitz RP, Caplan ES. Management of infections in the trauma patient. Surg Clin North Am 1999; 79:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/42\">",
"      Einhorn A, Mizrahi EM. Basilar skull fractures in children. The incidence of CNS infection and the use of antibiotics. Am J Dis Child 1978; 132:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/43\">",
"      Brodie HA, Thompson TC. Management of complications from 820 temporal bone fractures. Am J Otol 1997; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/44\">",
"      Curry DJ, Frim DM. Delayed repair of open depressed skull fracture. Pediatr Neurosurg 1999; 31:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/45\">",
"      Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-9):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/46\">",
"      van den Heever CM, van der Merwe DJ. Management of depressed skull fractures. Selective conservative management of nonmissile injuries. J Neurosurg 1989; 71:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/47\">",
"      Kuhl DA, Boucher BA, Muhlbauer MS. Prophylaxis of posttraumatic seizures. DICP 1990; 24:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/48\">",
"      Lewis RJ, Yee L, Inkelis SH, Gilmore D. Clinical predictors of post-traumatic seizures in children with head trauma. Ann Emerg Med 1993; 22:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13704/abstract/49\">",
"      Makkat S, Vandevenne JE, Parizel PM, De Schepper AM. Multiple growing fractures and cerebral venous anomaly after penetrating injuries: delayed diagnosis in a battered child. Pediatr Radiol 2001; 31:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6563 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13704=[""].join("\n");
var outline_f13_24_13704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Linear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Comminuted",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Depressed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Open",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Linear skull fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Depressed skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Basilar skull fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Growing skull fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skull radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Isolated skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Open skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Basilar skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Depressed skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Growing skull fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6563|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/54/16237\" title=\"picture 1\">",
"      Raccoon eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 2\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1A\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/18/8492\" title=\"table 1B\">",
"      Childrens coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=related_link\">",
"      Nasal trauma and fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=related_link\">",
"      Prevention of falls in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13705="Definition and diagnosis of mitral valve prolapse";
var content_f13_24_13705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and diagnosis of mitral valve prolapse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Sorin Pislaru, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Maurice Enriquez-Sarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13705/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/24/13705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28356697\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse (MVP) is a common cause of mitral regurgitation (MR). Although most patients with MVP have mild, trivial, or no MR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/1\">",
"     1",
"    </a>",
"    ], it is the most common cause of surgical MR in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/2\">",
"     2",
"    </a>",
"    ]. Other potential complications include infective endocarditis and arrhythmias. The diagnosis of MVP is suspected on physical examination and confirmed by echocardiography.",
"   </p>",
"   <p>",
"    The definition, classification, etiology, pathology, and diagnosis of MVP will be reviewed here. Other aspects of MVP and associated MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356738\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of MVP in the general population varies among studies, mostly due to variable criteria used for diagnosis. Reports published early in the development of echocardiography suggested high MVP prevalence, 4 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and even close to 20 percent in selected populations. These early reports are now considered inaccurate because echocardiographic criteria for diagnosis were not yet fully developed and lacked specificity.",
"   </p>",
"   <p>",
"    Using currently accepted definition of MVP, the Framingham Heart Study reported an overall prevalence of 2.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/6\">",
"     6",
"    </a>",
"    ]. Individuals with classic MVP (leaflet thickness &ge;5 mm; 1.3 percent) and non-classic MVP (leaflet thickness &lt;5mm; 1.1 percent) had similar age and sex distributions. In another population-based study (Cardia), the prevalence of MVP in 4136 young adults was only 0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/7\">",
"     7",
"    </a>",
"    ]. In a Canadian study of 972 patients, MVP prevalence was similar in three ethnic groups (2.7 percent in South Asian, 3.1 percent in European, and 2.2 percent in Chinese) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/8\">",
"     8",
"    </a>",
"    ]. MVP patients were leaner and had a greater degree of mitral regurgitation than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is unclear whether prevalence differences between studies are age-related and should be interpreted as demonstrating a link between aging and MVP prevalence.",
"   </p>",
"   <p>",
"    Mitral valve prolapse may be slightly more common in women than in men. In the Framingham study, there was a nonsignificant trend toward a female preponderance among those with MVP (59.5 versus 52.7 percent in those without MVP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/6\">",
"     6",
"    </a>",
"    ]; in the larger Olmsted county study, 64 percent of individuals with MVP were women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with MVP have MR (70 percent in one cross-sectional population-based study), but most patients with MVP (approximately 75 percent in the same study) have mild, trace, or no MR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/1\">",
"     1",
"    </a>",
"    ]. Severe MR is uncommon, identified in 4 percent of patients with MVP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356750\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MVP was previously based upon a combination of clinical exam findings and echocardiographic criteria and is now defined echocardiographically.",
"   </p>",
"   <p>",
"    The current echocardiographic definition of MVP is billowing of any portion of the mitral leaflets &ge;2 mm above the annular plane in a long axis view (parasternal or apical three-chamber) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83594 \" href=\"UTD.htm?13/9/13462\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/10\">",
"     10",
"    </a>",
"    ]. Prolapse of the mitral valve is defined as an abnormal systolic displacement of one or both leaflets into the left atrium (systolic billowing) due to a disruption or elongation of leaflets, chordae, or papillary muscles. This abnormal movement has been challenging to define due to the saddle shape of the mitral annulus and the commissural systolic descent towards the ventricular apex. Thus, in the apical four chamber view, the leaflets may appear posterior to the annulus, even in a completely normal subject [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. These observations published in the late 1980s led to a change in the accepted echocardiographic view for identification of MVP from &ldquo;any view&rdquo; to &ldquo;a (three chamber) long-axis view&rdquo;. &nbsp;",
"   </p>",
"   <p>",
"    Historically, while a mid-systolic click and late-systolic murmur were described in the late 19",
"    <sup>",
"     th",
"    </sup>",
"    century, their association with mitral regurgitation was first demonstrated by Barlow in 1963 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/13\">",
"     13",
"    </a>",
"    ]. The relationship between the late systolic click-murmur and abnormal mitral motion was further characterized in a larger series of 90 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/14\">",
"     14",
"    </a>",
"    ]. MVP was subsequently linked to numerous symptoms and clinical syndromes, but many studies finding associations with MVP used variable and insufficiently stringent diagnostic criteria. In addition, many names have been used for MVP in the literature (click-murmur syndrome, Barlow&rsquo;s disease, myxomatous mitral valve disease, floppy mitral valve, etc), leading to further confusion. Diagnostic criteria for MVP have evolved from being based on physical examination (with auscultatory findings considered diagnostic even with a normal echocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]) to including overbroad echocardiographic criteria (including findings on M-mode and in the four-chamber view) to the current criteria.",
"   </p>",
"   <p>",
"    Since diagnostic criteria for MVP have evolved, the literature on MVP must be reviewed with care. Many studies of MVP have design flaws due to inadequate controls",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insufficiently stringent criteria for MVP. In addition, patients previously misdiagnosed with MVP require appropriate evaluation and counseling.",
"   </p>",
"   <p>",
"    There are multiple ways of classifying MVP, underscoring the heterogeneity of this disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Etiologically, MVP is classified as primary (degenerative disease in the absence of identifiable connective tissue disease, sporadic or familial) versus secondary MVP (associated with an identifiable disorder such as Marfan syndrome) (",
"      <a class=\"graphic graphic_table graphicRef83655 \" href=\"UTD.htm?24/57/25500\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Clinically, MVP can be classified as syndromic when extra-cardiac manifestations are present (eg, pectus excavatum) versus non-syndromic, isolated MVP. The etiologies and mechanisms of regurgitation in various forms of MVP are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef83655 \" href=\"UTD.htm?24/57/25500\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      MVP is also classified by severity of the abnormal movement of the valve. The leaflets are described as billowing when the tips of leaflets remain in the LV versus flail when the tip(s) of one (or both) leaflets prolapses into the LA. &nbsp;",
"     </li>",
"     <li>",
"      Morphologically, MVP is classified as classic (also known as Barlow&rsquo;s syndrome with markedly and diffusely thickened leaflets [&ge;5 mm] with bileaflet prolapse) versus non-classic (with limited or absent thickening [thickness &lt;5mm] and segmental prolapse). (See",
"      <a class=\"local\" href=\"#H28356921\">",
"       'Pathology'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H28356780\">",
"       'Primary MVP'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Doppler echocardiography can also distinguish MVP without mitral regurgitation (MR) from MVP with MR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356780\">",
"    <span class=\"h1\">",
"     PRIMARY MVP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356796\">",
"    <span class=\"h2\">",
"     Sporadic primary MVP",
"    </span>",
"    &nbsp;&mdash;&nbsp;MVP is the most common cause of organic severe mitral regurgitation in the Western world [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/17\">",
"     17",
"    </a>",
"    ] and is characterized by myxomatous degeneration of the mitral valve leaflet(s) in the absence of a recognizable connective tissue disorder. The degree of involvement of the mitral valve leaflets and chords is variable, and results in a continuous spectrum of disease varying from &ldquo;classic&rdquo; to &ldquo;non-classic&rdquo; disease as described below. (See",
"    <a class=\"local\" href=\"#H28356921\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Primary MVP can be associated with other valvular abnormalities (tricuspid valve in up to 40 to 50 percent of patients, and aortic valve in 10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/10,18,19\">",
"     10,18,19",
"    </a>",
"    ], thoracic skeletal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], von Willebrand syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/22\">",
"     22",
"    </a>",
"    ], and hypomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/23\">",
"     23",
"    </a>",
"    ]. The latter two associations suggest that MVP may be related to a linked mesenchymal dysplasia, although hypomastia may also be a simple reflection of patients&rsquo; lean body habitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356823\">",
"    <span class=\"h2\">",
"     Familial primary MVP",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most of the cases of primary MVP are sporadic, familial cases have been identified since at least 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The most common transmission pattern is autosomal dominant with incomplete penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/24\">",
"     24",
"    </a>",
"    ]. The prevalence in first degree relatives is relatively high, ranging from 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Three loci have been mapped to chromosomes 16, 11, and 13, but the underlying genetic defects are not currently known [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An X-linked recessive form seems to be related to filamin A mutations, and results in a rare form of multivalvular myxomatous degeneration (X-linked myxomatous valvular dystrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In affected males, this disease is characterized by myxomatous degeneration of the mitral valve frequently associated with aortic valve degeneration. Female carriers can also exhibit valvular degeneration, but this is usually less severe.",
"   </p>",
"   <p>",
"    Echocardiography is indicated for formal diagnosis in patients with a family history of MVP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356838\">",
"    <span class=\"h1\">",
"     SECONDARY MVP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356854\">",
"    <span class=\"h2\">",
"     Secondary MVP associated with connective tissue disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;MVP is more prevalent in patients with Marfan syndrome, MASS phenotype, Ehlers&ndash;Danlos syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/24,29\">",
"     24,29",
"    </a>",
"    ]. Among patients with Marfan syndrome, mitral valve prolapse occurs more frequently in patients with FBN1 mutations as compared to those with TGFBR2 mutations (eg, 45 and 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/30\">",
"     30",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356868\">",
"    <span class=\"h2\">",
"     Secondary MVP due to mechanisms other than myxomatous degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other diseases are associated with imbalance of the mitral valve complex, leading to prolapse and flail of the mitral valve. Infective endocarditis causes destructive lesions, and ruptured chordae may ensue, leading to flail mitral leaflet(s). Myocardial ischemia is not a cause of MVP, but myocardial infarction with papillary muscle rupture causes one or both leaflets to prolapse in the LA, often with a muscle tip attached. Similarly, blunt chest trauma with rupture of chordae or papillary muscle can cause a flail mitral leaflet. Acute rheumatic fever may cause prolapse by true elongation of the valvular tissue, but chronically, tissue retraction makes the occurrence of a prolapse due to rheumatic fever exceptional unless there is a ruptured chord.",
"   </p>",
"   <p>",
"    Other diseases, such as hypertrophic cardiomyopathy, myxomas, or prominent mitral annular calcifications, may also cause ruptured chordae and thereby cause leaflet prolapse. While mitral regurgitation in these cases is technically due to leaflet prolapse, the diagnosis is usually obvious from the clinical presentation and echocardiographic findings, and not associated with myxomatous degeneration of the leaflets.",
"   </p>",
"   <p>",
"    MVP has also been found in as many as 15 percent of patients with Ebstein's anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .) This suggests a role for LV deformation in creating mitral imbalance and prolapse despite a structurally normal mitral valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356921\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomically, the mitral valve is formed by a long and narrow anterior leaflet and a shorter and wider posterior leaflet occupying a larger portion of the annular circumference (",
"    <a class=\"graphic graphic_figure graphicRef83654 \" href=\"UTD.htm?30/62/31715\">",
"     figure 1",
"    </a>",
"    ). Thus, when the mitral valve is closed it appears from the atrial side as the &ldquo;mitral smile&rdquo; with two leaflets and two commissures (anterolateral and posteromedial). The leaflets&rsquo; bases are attached to the annulus and their tips to the chordae, which join the papillary muscles.",
"   </p>",
"   <p>",
"    In primary and secondary MVP associated with connective tissue disorders, the degenerative process may involve the entire mitral valvular complex (leaflets, chordae, mitral annulus). The hallmark macroscopic valvular lesion of MVP is excessive mitral leaflet tissue leading to folding and hooding. Depending on the extent of the myxomatous degeneration, one or more segments of one or both leaflets are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The chordae are elongated, have reduced strength, and may rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/34\">",
"     34",
"    </a>",
"    ]. The annulus is typically dilated and frequently disjuncted from its normal myocardial support. In contrast, the papillary muscles are usually normal in structure. Physiologically, various combinations of the leaflet, chordal, and annular alterations yield insufficient apposition of the rough zones of the leaflets so they no longer support each other during systole and fall into the left atrium.",
"   </p>",
"   <p>",
"    While there is great diversity of lesions, the macro-alterations of MVP are often grouped under two headings. At one end of the spectrum is &ldquo;classic&rdquo; (also known as Barlow&rsquo;s disease or diffuse myxomatous) MVP, characterized by thickened and diffusely redundant myxomatous leaflet tissue with prolapse of most of the leaflet segments, severe mitral annular enlargement, and elongated (rarely ruptured) chords (",
"    <a class=\"graphic graphic_figure graphicRef83595 \" href=\"UTD.htm?17/43/18104\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef83604 graphicRef83605 \" href=\"UTD.htm?40/54/41830\">",
"     movie 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/35\">",
"     35",
"    </a>",
"    ]. Mitral annular disjunction is an abnormality of the mitral annulus fibrosus resulting in a systolic gap between the insertion of the posterior mitral leaflet and the basal inferolateral myocardium (",
"    <a class=\"graphic graphic_movie graphicRef83606 \" href=\"UTD.htm?18/25/18833\">",
"     movie 2",
"    </a>",
"    ). This disjunction commonly occurs in patients with advanced classic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the other end is &ldquo;non-classic&rdquo; disease known as fibroelastic deficiency first described by Carpentier [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/37\">",
"     37",
"    </a>",
"    ], which can be seen in up to 40 percent of patients requiring mitral valve repair. It usually affects individuals over the age of 60 and is characterized by involvement of a single segment (most commonly P2 scallop), with thin and somewhat redundant leaflets, ruptured chords, and mild mitral annular enlargement (",
"    <a class=\"graphic graphic_figure graphicRef83595 \" href=\"UTD.htm?17/43/18104\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef83602 graphicRef83603 \" href=\"UTD.htm?24/12/24775\">",
"     movie 3A-B",
"    </a>",
"    ). The flail segment is thickened and myxomatous in a very localized manner.",
"   </p>",
"   <p>",
"    Forme fruste Barlow&rsquo;s disease appears as an intermediate between classic and non-classic disease. It is important to make the distinction between various forms, as the complexity of surgical repair increases with the extent of mitral valve involvement by myxomatous degeneration.",
"   </p>",
"   <p>",
"    Histologically, the characteristic myxomatous lesion is proliferation of the spongiosa of the mitral valve leaflets, with mucopolysaccharide deposits and excessive water content causing leaflet thickening and redundancy. The collagen composition is altered, with a marked increase in type III collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/33\">",
"     33",
"    </a>",
"    ]; elastin fibers appear fragmented [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/34\">",
"     34",
"    </a>",
"    ]. Focal accumulation of activated valvular interstitial cells and increased expression of matrix metalloproteinases suggest that abnormal tissue remodeling is responsible for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Qualitative histological analysis cannot differentiate between Barlow&rsquo;s disease and fibroelastic deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/39\">",
"     39",
"    </a>",
"    ]. However, a more elaborate semiquantitative analysis shows different patterns, with more myxomatous infiltration, collagen proliferation, and elastic fiber lesions in Barlow&rsquo;s disease and Marfan syndrome than in fibroelastic deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356936\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since symptoms do not reliably indicate MVP, the key clinical manifestations of MVP are auscultatory findings that lead to evaluation by echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406765\">",
"    <span class=\"h2\">",
"     MVP syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous nonspecific symptoms and signs such as chest pain, palpitations, dyspnea, exercise intolerance, dizziness, anxiety disorders, and electrocardiographic abnormalities have been attributed to MVP. MVP syndrome has been defined as the combination of these symptoms and signs with mitral valve prolapse. However, the validity of MVP syndrome has been questioned since many reports of associations had flawed study designs (including inadequate control groups and use of insufficiently stringent diagnostic criteria for MVP). These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356943\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, various nonspecific symptoms such as palpitations, dyspnea, exercise intolerance, and dizziness have been attributed to MVP. However, symptoms are not reliable indicators of MVP. Furthermore, symptoms frequently seen in individuals with MVP have not been conclusively determined to be more prevalent than in the general population. As an example, in a study of 147 patients referred for echocardiography for suspected MVP, the presence of symptoms was not associated with MVP on echocardiography (found in 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While MVP represents the main cause of severe organic MR in the developed countries, only a minority of patients with MVP ultimately develop severe MR due to profound leaflet prolapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chordal rupture (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With chronic severe MR, most patients remain asymptomatic for years and the development of symptoms is generally insidious with time or at the onset of atrial fibrillation. The most common symptom of severe MR is dyspnea. Fatigue is a much less specific symptom and thus less likely to improve after surgery.",
"     </li>",
"     <li>",
"      A less common presentation is the chordal rupture syndrome whereby acute severe MR causes sudden dyspnea, chest pressure, and often rapidly progressive pulmonary edema. Hypotension and other signs of shock occur in rare cases.",
"     </li>",
"     <li>",
"      When acute MR progression is superimposed upon chronic MR, patients may present more subacutely with progressive dyspnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28356962\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406806\">",
"    <span class=\"h3\">",
"     Cardiac examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common auscultatory features of mitral valve prolapse are the non-ejection click (single or multiple) and the murmur of mitral regurgitation. The click is thought to be caused by snapping of the mitral chordae during systole when the valve bows into the atrium. The click is mobile, meaning its timing varies with maneuvers that change the left ventricular volume, occurring earlier in systole with sitting, standing, or other interventions that reduce ventricular size, or later with those interventions that increase chamber size such as squatting (",
"    <a class=\"graphic graphic_movie graphicRef57858 \" href=\"UTD.htm?7/55/8051\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80360 \" href=\"UTD.htm?15/40/16004\">",
"     movie 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/41\">",
"     41",
"    </a>",
"    ]. An MVP click should be differentiated from the aortic or pulmonary ejection clicks (occurring early in systole, at the foot of the carotid upstroke) and from other cardiac sounds (split first or second heart sounds, pericardial sounds, atrial septal aneurysm clicks). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, most adults with MVP have mitral regurgitation (MR), but the majority of patients with MVP have mild, trace, or no MR, and severe MR is uncommon. (See",
"    <a class=\"local\" href=\"#H28356738\">",
"     'Epidemiology'",
"    </a>",
"    above.) The murmur of mitral regurgitation with MVP is late-systolic early in the course of the disease, and its point of maximal intensity and radiation pattern varies with the direction of the jet (anteriorly-directed jets can be heard over the entire precordial area, while posteriorly directed jets are typically best heard at the apex and radiate towards the axilla and the back). Once a flail or severe prolapse occurs, the murmur becomes holosystolic and is indistinguishable in tone from other causes of mitral regurgitation, but often will remain maximum at mid-late systole. With long-standing severe mitral regurgitation, apical impulse is displaced laterally, and clinical findings of LV dysfunction (gallop sounds) and pulmonary hypertension (loud P2 component) can be found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With acute severe MR (as may result from chordal rupture) the cardiac impulse is hyperdynamic but normal in location unless there has been preceding chronic MR. The murmur of acute MR may be early systolic, midsystolic, or holosystolic and is generally soft and low pitched, ending before A2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data are available on the diagnostic accuracy of auscultation for MVP, particularly when limited to studies using current echocardiographic diagnostic criteria. Identification of a mobile systolic click by an expert observer may be a highly sensitive finding (88 and 100 percent) with fair specificity (66 and 73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In contrast, in a study of 147 patients referred for echocardiography for suspected MVP, identification of a systolic click by a referring physician had a sensitivity of 52 percent and specificity of 68 percent for MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/40\">",
"     40",
"    </a>",
"    ]. Of note, auscultatory manifestations are highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/41\">",
"     41",
"    </a>",
"    ]. This, together with inconsistent clinical examination skills among physicians and variable auscultatory and echocardiographic criteria used to diagnose MVP, probably explains the conflicting observations on the accuracy of auscultatory findings in MVP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406867\">",
"    <span class=\"h3\">",
"     Other physical examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation of the general appearance and body habitus is usually the first step in the physical examination. Skeletal abnormalities found in patients with MVP include narrow anteroposterior chest diameter, scoliosis and loss of kyphosis of the thoracic spine, and pectus excavatum deformity, although the data on the frequency of MVP in patients with these abnormalities are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/20,21,44\">",
"     20,21,44",
"    </a>",
"    ]. Patients with MVP tend to have a lower BMI index than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357003\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H407051\">",
"    <span class=\"h2\">",
"     M-mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode echocardiography should no longer be used in making a positive diagnosis of MVP. Previously used M-mode criteria for MVP are not reliable because the normal motion of the base of the heart can either mask or mimic true prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17834230\">",
"    <span class=\"h2\">",
"     2D echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leaflet displacement &ge;2 mm above the plane of the mitral annulus in long axis views (parasternal or apical three-chamber) is the accepted criterion for a positive diagnosis of MVP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83594 \" href=\"UTD.htm?13/9/13462\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/10\">",
"     10",
"    </a>",
"    ]. Other 2D features associated with MVP are abnormalities in leaflet length, annular diameter (enlarged), and chordal length (elongated).",
"   </p>",
"   <p>",
"    When surgical intervention is contemplated, knowledge of the detailed mitral valve anatomy is needed to effectively communicate the necessary information to the surgical team. The anatomical description of the mitral valve proposed by Carpentier (",
"    <a class=\"graphic graphic_figure graphicRef83654 \" href=\"UTD.htm?30/62/31715\">",
"     figure 1",
"    </a>",
"    ) divides the posterior leaflet into anterolateral (P1), middle (P2), and postero-medial (P3) scallops. While the anterior leaflet does not have obvious anatomical divisions, corresponding segments are labeled similarly A1 to A3. Expert examination of the mitral valve at transthoracic echocardiography (TTE) enables determination of the location and extent of disease for pre-operative planning in up to 98 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/45\">",
"     45",
"    </a>",
"    ], although 2D and 3D transesophageal echocardiography (TEE) provide superior delineation of the anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/46\">",
"     46",
"    </a>",
"    ]. Intra-operative TEE is recommended for mitral valve cases; image quality is superior to TTE and allows detecting finer anatomic details (ruptured chords, more precise location of origin of mitral regurgitant jet). Information about the location, extent of disease, and origin(s) of the mitral regurgitant jet needs to be communicated to the surgical team for adequate planning. Surgical intervention for classic MVP is likely to involve a significantly more complex approach than needed for localized fibroelastic deficiency seen with non-classic MVP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357037\">",
"    <span class=\"h2\">",
"     3D echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of 3D technology, especially real time 3D-TEE, provides excellent rendering of the mitral valve complex. Live 3D TEE has become routine in",
"    <span class=\"nowrap\">",
"     pre/intraoperative",
"    </span>",
"    imaging of the mitral valve and in percutaneous mitral valve interventions. 3D TEE efficiently identifies correct location of prolapse and flail segments, and by reconstruction of the 3D image from the left atrial view (surgical view), information is easily communicated to the surgical team (",
"    <a class=\"graphic graphic_figure graphicRef83654 \" href=\"UTD.htm?30/62/31715\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef83603 graphicRef83605 \" href=\"UTD.htm?17/28/17863\">",
"     movie 1B, 3B",
"    </a>",
"    ). Furthermore, live 3D TEE allows insights into the dynamic mitral annulus function, with early-systolic area contraction and saddle-shape deepening contributing to mitral competency. The mitral annulus in MVP is also dynamic but considerably different from normal patients, with loss of early-systolic area contraction and diminished saddle-shape deepening despite similar magnitude of ventricular contraction, suggestive of ventricular-annular decoupling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357056\">",
"    <span class=\"h2\">",
"     Doppler imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;While 2D and 3D imaging techniques allow identification of anatomical substrate, Doppler echocardiographic techniques are key to estimating severity of MR. The criteria used to diagnose severe MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Severity of mitral regurgitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    MR severity should be quantitated in all patients with a visual appearance of greater than mild MR on Color Doppler. Formal quantification of mitral valve severity not only minimizes errors intrinsic to Color Doppler visual quantification of severity, but also provides essential information about a patient&rsquo;s individual risk. Quantitative measures of MR (regurgitant volume and orifice) are essential predictors of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/48\">",
"     48",
"    </a>",
"    ] as confirmed in two independent prospective studies totaling more than 1000 patients followed long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H407085\">",
"    <span class=\"h1\">",
"     OTHER IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357101\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging is an emerging tool in assessment of valvular heart disease. Small studies have shown that MVP can be diagnosed by CMR and focal late gadolinium enhancement of mitral valve leaflets and papillary muscles has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/51\">",
"     51",
"    </a>",
"    ]. The clinical utility of this approach has not been evaluated. CMR also enables quantification of MR as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H21658413#H21658413\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Regurgitant valve disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357115\">",
"    <span class=\"h2\">",
"     Left ventricular angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is not used to diagnose MVP. However, in some patients referred for cardiac catheterization, MVP may be incidentally found on left ventricular angiography, showing the displacement of the mitral valve leaflets into the left atrium with late systolic MR. These patients should be further evaluated by echocardiography. In addition, hemodynamic catheterization and LV angiography are used for assessment of MR severity in patients with discordant clinical and echocardiographic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21670309\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination remains the key step in making a diagnosis of mitral valve prolapse. The auscultatory findings of non-ejection clicks and systolic murmur are the initial observations leading to a diagnosis by echocardiography. On two-dimensional echocardiography, leaflet displacement &ge;2 mm above the plane of the mitral annulus in long axis views (parasternal or apical three-chamber) is the accepted criterion for a positive diagnosis of MVP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83594 \" href=\"UTD.htm?13/9/13462\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/10\">",
"     10",
"    </a>",
"    ]. Echocardiography provides information not only about the presence (or absence) of mitral leaflet prolapse, but also allows a comprehensive evaluation of the subvalvular structures, assessment of mitral regurgitation, and of hemodynamic consequences. &nbsp;",
"   </p>",
"   <p>",
"    As noted in the 2008 update of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease, echocardiography is indicated for formal diagnosis in patients with clinical examination suggestive of MVP and in patients with a family history of MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13705/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21670405\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with mitral regurgitation, MVP should be distinguished from other causes of MR which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       \"Patient information: Mitral valve prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28357141\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MVP is a complex entity, with significant confusion in the literature related to use of variable denominations, definitions, and diagnostic criteria. (See",
"      <a class=\"local\" href=\"#H28356750\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The prevalence of MVP in the United States is estimated at 0.6 to 2.4 percent, which is significantly lower than previously reported. This estimate is lower due to the current use of a more stringent definition of MVP. (See",
"      <a class=\"local\" href=\"#H28356738\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MVP is classified as primary (sporadic or familial forms; no other identifiable disease) or secondary (associated with identifiable connective tissue disorder or associated with other non-myxomatous mitral valve disease). (See",
"      <a class=\"local\" href=\"#H28356750\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morphologically, MVP is classified as classic (with markedly and diffusely thickened leaflets [&ge;5 mm] with bileaflet prolapse) versus non-classic (with limited or absent leaflet thickening [thickness &lt;5mm] and segmental prolapse). (See",
"      <a class=\"local\" href=\"#H28356750\">",
"       'Definition and classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28356921\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical examination remains the first step in diagnosis of MVP. The non-ejection click is mobile, meaning that the timing varies with maneuvers that alter left ventricular volume. The mitral regurgitant murmur can be late systolic (early in the disease) or holosystolic (severe prolapse or flail). (See",
"      <a class=\"local\" href=\"#H28356962\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Echocardiography is the key imaging study in the diagnosis of MVP. Prolapse is defined as systolic mitral leaflet displacement &ge;2 mm above the annular plane in the parasternal or apical long axis views. (See",
"      <a class=\"local\" href=\"#H28356750\">",
"       'Definition and classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17834230\">",
"       '2D echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Echocardiography is indicated for formal diagnosis in patients with clinical examination suggestive of MVP or those with a family history of MVP. (See",
"      <a class=\"local\" href=\"#H28357003\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intra-operative TEE, especially live 3D TEE, provides excellent diagnostic accuracy and helps surgical planning. (See",
"      <a class=\"local\" href=\"#H28357037\">",
"       '3D echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Formal quantification of MR severity is indicated in all patients with more than mild MR, as it provides reliable prognostic information in patients with MVP. (See",
"      <a class=\"local\" href=\"#H28357056\">",
"       'Doppler imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10553072\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Matthew J. Sorrentino for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/1\">",
"      Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002; 40:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/2\">",
"      Luxereau P, Dorent R, De Gevigney G, et al. Aetiology of surgically treated mitral regurgitation. Eur Heart J 1991; 12 Suppl B:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/3\">",
"      Procacci PM, Savran SV, Schreiter SL, Bryson AL. Prevalence of clinical mitral-valve prolapse in 1169 young women. N Engl J Med 1976; 294:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/4\">",
"      Darsee JR, Mikolich JR, Nicoloff NB, Lesser LE. Prevalence of mitral valve prolapse in presumably healthy young men. Circulation 1979; 59:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/5\">",
"      Hickey AJ, Wolfers J, Wilcken DE. Mitral-valve prolapse: prevalence in an Australian population. Med J Aust 1981; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/6\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/7\">",
"      Flack JM, Kvasnicka JH, Gardin JM, et al. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J 1999; 138:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/8\">",
"      Theal M, Sleik K, Anand S, et al. Prevalence of mitral valve prolapse in ethnic groups. Can J Cardiol 2004; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/9\">",
"      Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/10\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/11\">",
"      Levine RA, Handschumacher MD, Sanfilippo AJ, et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 1989; 80:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/12\">",
"      Levine RA, Triulzi MO, Harrigan P, Weyman AE. The relationship of mitral annular shape to the diagnosis of mitral valve prolapse. Circulation 1987; 75:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/13\">",
"      BARLOW JB, POCOCK WA. The significance of late systolic murmurs and mid-late systolic clicks. Md State Med J 1963; 12:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/14\">",
"      Barlow JB, Bosman CK, Pocock WA, Marchand P. Late systolic murmurs and non-ejection (\"mid-late\") systolic clicks. An analysis of 90 patients. Br Heart J 1968; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/15\">",
"      Devereux RB, Kramer-Fox R, Shear MK, et al. Diagnosis and classification of severity of mitral valve prolapse: methodologic, biologic, and prognostic considerations. Am Heart J 1987; 113:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/16\">",
"      Perloff JK, Child JS, Edwards JE. New guidelines for the clinical diagnosis of mitral valve prolapse. Am J Cardiol 1986; 57:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/17\">",
"      de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. J Card Surg 2011; 26:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/18\">",
"      Morganroth J, Jones RH, Chen CC, Naito M. Two dimensional echocardiography in mitral, aortic and tricuspid valve prolapse. The clinical problem, cardiac nuclear imaging considerations and a proposed standard for diagnosis. Am J Cardiol 1980; 46:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/19\">",
"      Ogawa S, Hayashi J, Sasaki H, et al. Evaluation of combined valvular prolapse syndrome by two-dimensional echocardiography. Circulation 1982; 65:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/20\">",
"      Bon Tempo CP, Ronan JA Jr, de Leon AC Jr, Twigg HL. Radiographic appearance of the thorax in systolic click-late systolic murmur syndrome. Am J Cardiol 1975; 36:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/21\">",
"      Kelly RE, Goretsky MJ, Obermeyer R, et al. Twenty-one years of experience with minimally invasive repair of pectus excavatum by the Nuss procedure in 1215 patients. Ann Surg 2010; 252:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/22\">",
"      Pickering NJ, Brody JI, Barrett MJ. von Willebrand syndromes and mitral-valve prolapse; linked mesenchymal dysplasias. N Engl J Med 1981; 305:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/23\">",
"      Rosenberg CA, Derman GH, Grabb WC, Buda AJ. Hypomastia and mitral-valve prolapse. Evidence of a linked embryologic and mesenchymal dysplasia. N Engl J Med 1983; 309:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/24\">",
"      Grau JB, Pirelli L, Yu PJ, et al. The genetics of mitral valve prolapse. Clin Genet 2007; 72:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/25\">",
"      Strahan NV, Murphy EA, Fortuin NJ, et al. Inheritance of the mitral valve prolapse syndrome. Discussion of a three-dimensional penetrance model. Am J Med 1983; 74:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/26\">",
"      Scheele W, Allen HN, Kraus R, et al. Familial prevalence and genetic transmission of mitral valve prolapse. Circulation 1977; 56 (Suppl. 3):111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/27\">",
"      Monteleone PL, Fagan LF. Possible X-linked congenital heart disease. Circulation 1969; 39:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/28\">",
"      Lardeux A, Kyndt F, Lecointe S, et al. Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects. J Cardiovasc Transl Res 2011; 4:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/29\">",
"      Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 1989; 262:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/30\">",
"      Attias D, Stheneur C, Roy C, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 2009; 120:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/31\">",
"      Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/32\">",
"      Lucas RV Jr, Edwards JE. The floppy mitral valve. Curr Probl Cardiol 1982; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/33\">",
"      Cole WG, Chan D, Hickey AJ, Wilcken DE. Collagen composition of normal and myxomatous human mitral heart valves. Biochem J 1984; 219:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/34\">",
"      Barber JE, Kasper FK, Ratliff NB, et al. Mechanical properties of myxomatous mitral valves. J Thorac Cardiovasc Surg 2001; 122:955.",
"     </a>",
"    </li>",
"    <li>",
"     Adams DH, Carabello BA, Castillo J. Mitral valve regurgitation. In: Hurst's The Heart, 13th ed, Fuster V, Walsh RA, Harrington RA.  (Eds), McGraw-Hill, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/36\">",
"      Eriksson MJ, Bitkover CY, Omran AS, et al. Mitral annular disjunction in advanced myxomatous mitral valve disease: echocardiographic detection and surgical correction. J Am Soc Echocardiogr 2005; 18:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/37\">",
"      Carpentier A, Lacour-Gayet F, Camilleri J, et al. Fibroelastic dysplasia of the mitral valve. An anatomical clinical entity. Circulation 1980; 62 (Suppl. III):111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/38\">",
"      Prunotto M, Caimmi PP, Bongiovanni M. Cellular pathology of mitral valve prolapse. Cardiovasc Pathol 2010; 19:e113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/39\">",
"      Fornes P, Heudes D, Fuzellier JF, et al. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: a histomorphometric study of 130 excised segments. Cardiovasc Pathol 1999; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/40\">",
"      Heidenreich PA, Bear J, Browner W, Foster E. The clinical impact of echocardiography on antibiotic prophylaxis use in patients with suspected mitral valve prolapse. Am J Med 1997; 102:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/41\">",
"      Devereux RB, Kramer-Fox R, Kligfield P. Mitral valve prolapse: causes, clinical manifestations, and management. Ann Intern Med 1989; 111:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/42\">",
"      Barron JT, Manrose DL, Liebson PR. Comparison of auscultation with two-dimensional and Doppler echocardiography in patients with suspected mitral valve prolapse. Clin Cardiol 1988; 11:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/43\">",
"      Weis AJ, Salcedo EE, Stewart WJ, et al. Anatomic explanation of mobile systolic clicks: implications for the clinical and echocardiographic diagnosis of mitral valve prolapse. Am Heart J 1995; 129:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/44\">",
"      Malcolm AD. Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance? Br Heart J 1985; 53:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/45\">",
"      Monin JL, Dehant P, Roiron C, et al. Functional assessment of mitral regurgitation by transthoracic echocardiography using standardized imaging planes diagnostic accuracy and outcome implications. J Am Coll Cardiol 2005; 46:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/46\">",
"      Pepi M, Tamborini G, Maltagliati A, et al. Head-to-head comparison of two- and three-dimensional transthoracic and transesophageal echocardiography in the localization of mitral valve prolapse. J Am Coll Cardiol 2006; 48:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/47\">",
"      Grewal J, Suri R, Mankad S, et al. Mitral annular dynamics in myxomatous valve disease: new insights with real-time 3-dimensional echocardiography. Circulation 2010; 121:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/48\">",
"      Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/49\">",
"      Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/50\">",
"      Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009; 119:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13705/abstract/51\">",
"      Han Y, Peters DC, Salton CJ, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging 2008; 1:294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8172 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13705=[""].join("\n");
var outline_f13_24_13705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28357141\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356697\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356738\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356750\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356780\">",
"      PRIMARY MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356796\">",
"      Sporadic primary MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356823\">",
"      Familial primary MVP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356838\">",
"      SECONDARY MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356854\">",
"      Secondary MVP associated with connective tissue disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356868\">",
"      Secondary MVP due to mechanisms other than myxomatous degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356921\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28356936\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H406765\">",
"      MVP syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356943\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28356962\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H406806\">",
"      - Cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H406867\">",
"      - Other physical examination findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28357003\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H407051\">",
"      M-mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17834230\">",
"      2D echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28357037\">",
"      3D echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28357056\">",
"      Doppler imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H407085\">",
"      OTHER IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28357101\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28357115\">",
"      Left ventricular angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21670309\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21670405\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28357141\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10553072\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8172|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/9/13462\" title=\"diagnostic image 1\">",
"      Identification of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8172|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31715\" title=\"figure 1\">",
"      Schematic and 3D echo of mitral valve leaflets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/43/18104\" title=\"figure 2\">",
"      Nonclassic and classic MVP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8172|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?5/25/5521\" title=\"movie 1A\">",
"      Three-chamber view of classic MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?1/8/1154\" title=\"movie 1B\">",
"      3D SHAX view of classic MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/25/18833\" title=\"movie 2\">",
"      PLAX view of classic MVP with annular disjunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/61/17362\" title=\"movie 3A\">",
"      PLAX view of nonclassic MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?5/36/5698\" title=\"movie 3B\">",
"      3D SHAX view of nonclassic MVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/55/8051\" title=\"movie 4\">",
"      Mitral valve prolapse with patient standing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/40/16004\" title=\"movie 5\">",
"      Mitral valve prolapse with patient squatting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/57/25500\" title=\"table 1\">",
"      Etiologies of MVP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13706="Effects of cytotoxic agents on gonadal function in adult men";
var content_f13_24_13706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effects of cytotoxic agents on gonadal function in adult men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Frances J Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Glenn J Bubley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/24/13706/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/24/13706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant advances have been made in the treatment of a number of malignancies in men. Increasing interest has therefore been focused on the late toxicities of cancer chemotherapy in long-term survivors. One of the most common long-term side effects of cytotoxic agents in men is gonadal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The following general rules apply to the gonadal toxicity of chemotherapy in the male.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spermatogenesis is much more likely to be disrupted than is testosterone production, because the germinal epithelium of the testis is more sensitive to damage from cytotoxic drugs than the Leydig cells.",
"     </li>",
"     <li>",
"      The degree of damage to the germinal epithelium is influenced by the stage of sexual maturation of the testis. In general, the postpubertal testis appears to be more susceptible to damage than the prepubertal testis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The magnitude of the effect on sperm production is both drug-specific and dose-dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1,3,6-11\">",
"       1,3,6-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF DRUG-INDUCED INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of most cytotoxic chemotherapeutic agents is interference with obligatory cell processes, such as DNA synthesis, in the rapidly dividing cancer cells. However, all cells that undergo rapid division are susceptible to the toxic effects of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impact on the germinal epithelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the testis, the cells within the seminiferous tubules of the germinal epithelium have the highest mitotic and meiotic indices, and are thus most vulnerable to the toxic effects of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. While sperm counts begin to decline within a few weeks of chemotherapy, it typically takes two to three months for azoospermia to occur, in keeping with the known kinetics of spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Because antineoplastic agents act on the sperm cells during cell division, they are most toxic to the rapidly proliferating type B spermatogonia, which can be reproduced from the germinal stem cell layer. However, the severity and duration of gonadal damage induced by cytotoxic agents correlates best with the number of stem cells (type A spermatogonia) that are destroyed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/14\">",
"     14",
"    </a>",
"    ]. If the stem cells within the tubules remain intact, spermatogenesis may begin to show recovery approximately 12 weeks after treatment. Therefore, drugs that damage the stem cells are likely to cause permanent infertility. The typical histological pattern on testicular biopsy of patients who have received cytotoxic agents is atrophic tubules containing Sertoli cells lining the lumen, a few scattered spermatogonia and spermatids, and peritubular fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subtle effects on Sertoli cell function, including changes in cytokeratin expression and",
"    <span class=\"nowrap\">",
"     inhibin/follicle",
"    </span>",
"    stimulating hormone (FSH) ratios, have also been reported in adult men who underwent chemotherapy during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impact on Leydig cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less commonly, chemotherapy can damage Leydig cells, the site of testosterone production within the testis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1,3,4,17,18\">",
"     1,3,4,17,18",
"    </a>",
"    ]. However, Leydig cell dysfunction in this setting is typically subclinical, characterized by testosterone levels that are at the lower end of the normal range in association with elevated luteinizing hormone (LH) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinical significance of this state of \"compensated hypogonadism\" is still unclear. However, one randomized, placebo-controlled trial of testosterone replacement in 35 men with evidence of mild Leydig cell damage following treatment with cytotoxic chemotherapy for malignancy showed no beneficial impact of 12 months of supplemental testosterone on bone mineral density, body composition, lipids, or quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/19\">",
"     19",
"    </a>",
"    ]. In patients with testosterone levels that are clearly hypogonadal, however, testosterone replacement is a reasonable and safe strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMPACT OF CANCER ON GONADAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to bear in mind that certain tumors may also be associated with pretreatment abnormalities in testicular function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/3,20\">",
"     3,20",
"    </a>",
"    ], particularly Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], and germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/11,12,24-27\">",
"     11,12,24-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in pretreatment semen analysis are common in male patients with Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/3,20-23\">",
"     3,20-23",
"    </a>",
"    ]. Of 92 men with Hodgkin lymphoma studied prior to therapy, 67 percent had an abnormal semen sample in terms of sperm count (34 percent), motility (68 percent), or morphology (71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/23\">",
"     23",
"    </a>",
"    ]. In another study of 33 men with Hodgkin lymphoma, 12 (36 percent) had abnormalities in sperm count or motility prior to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/21\">",
"     21",
"    </a>",
"    ]. However, eight of nine patients (89 percent) who consented to testicular biopsy had histological evidence of damage to the seminiferous epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/21\">",
"     21",
"    </a>",
"    ]. Elevation of basal FSH levels occurred in 15 percent and LH in 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these pretreatment abnormalities, only 20 to 30 percent of men with Hodgkin lymphoma meet traditional criteria for sperm cryopreservation for intrauterine insemination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Semen cryopreservation'",
"    </a>",
"    below.) The precise pathophysiology of the gonadal damage in these patients is not clear, but no correlation has been observed either with the stage of disease or age at presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Testicular cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of men with testicular germ cell cancer (TGCC) have evidence of impaired spermatogenesis before any treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/3,11,20,24-26\">",
"     3,11,20,24-26",
"    </a>",
"    ] or after orchiectomy but before chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Cryopreservation of sperm'",
"    </a>",
"    .) In a review of 10 series of men with TGCC who were evaluated prior to chemotherapy, over one-half had oligospermia, 13 percent were azoospermic, and 30 percent had significant elevation in FSH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second series of 63 men with TGCC evaluated prior to orchiectomy, mean sperm concentrations were significantly lower than those of normal controls, 15 x",
"    <span class=\"nowrap\">",
"     10(6)/mL",
"    </span>",
"    versus 146 x",
"    <span class=\"nowrap\">",
"     10(6)/mL,",
"    </span>",
"    p&lt;0.001 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/26\">",
"     26",
"    </a>",
"    ]. Although a history of cryptorchidism was four times more common in patients with TGCC than in the controls (22 versus 5 percent), sperm counts remained significantly lower in men with testicular cancer even when those with cryptorchidism were excluded from the analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\", section on 'Cryptorchidism'",
"    </a>",
"    .) This preexisting suppression of spermatogenesis could not be explained by a general effect related to having a malignancy, as higher sperm counts were observed in a control group of men with lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of association between altered spermatogenesis and testicular cancer remains unclear. Histologically, suppression of spermatogenesis can be demonstrated in both the tumor-bearing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/31\">",
"     31",
"    </a>",
"    ] and the contralateral testis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/30\">",
"     30",
"    </a>",
"    ]. It has been proposed that factors secreted by the tumor, eg, human chorionic gonadotropin (hCG) or interleukins, may be implicated in the disruption of normal sperm production [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, an association between infertility and tumor gonadotropin production has not been shown by others [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/27\">",
"     27",
"    </a>",
"    ]. It is also possible that the germ cell defect in these patients is related to a defect in maturation of both testes that could predispose to cancer in one or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not as well documented as testicular cancer and Hodgkin lymphoma, men with acute leukemia may have poor pretreatment semen quality relative to healthy sperm donors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPEUTIC AGENTS ASSOCIATED WITH INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary source of information concerning the impact of cytotoxic drugs on fertility has been studies of patients receiving single agent chemotherapy, often for non-malignant conditions (eg, nephrotic syndrome or autoimmune diseases). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H81224860#H81224860\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Alkylating agents'",
"    </a>",
"    .) The chemotherapeutic agents with the most deleterious effect on male fertility are the alkylating agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    . These drugs all have cumulative dose ranges above which most patients will be rendered permanently infertile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The risk of alkylating agent-related infertility is dose, age, and gender-dependent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approximate minimum total dose at which gonadal toxicity begins to become a problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is 200 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in prepubertal males, and as little as 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in mature males [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/5,35\">",
"     5,35",
"    </a>",
"    ]. In one analysis of 116 men who had received cyclophosphamide as a single agent for renal disease (mean total dose 395",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    the incidence of gonadal dysfunction was 80 percent in men who received cumulative doses in excess of 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    doses of 6 to 10 g are likely to result in irreversible azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study designed to determine the threshold dose of cyclophosphamide that results in long-term infertility, semen analyses were performed before, during, and after cyclophosphamide-containing combination chemotherapy in men with advanced soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/36\">",
"     36",
"    </a>",
"    ]. Recovery of normal spermatogenesis was significantly more likely in men who received a cumulative dose of less than 7.5",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    compared with those receiving higher cumulative doses (70 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of the related drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    on long-term fertility is uncertain. In one report of 164 patients undergoing combination chemotherapy with or without ifosfamide for nonmetastatic extremity sarcoma, 10 of 12 men who were tested following treatment were azoospermic; nine had also received ifosfamide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a nonrandomized study of adolescents with sarcoma and non-Hodgkin lymphoma (median age 11.2 years)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    was associated with a lower risk of gonadal damage than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/38\">",
"     38",
"    </a>",
"    ]. After a median follow up of 10.7 years, FSH levels were elevated in 47.5 percent of patients who had received cyclophosphamide versus 6 percent of those treated with ifosfamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chlorambucil",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , cumulative doses up to 400 mg are associated with progressive but reversible oligospermia, while doses in excess of this result in irreversible damage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    doses &gt;400",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    result in permanent infertility in approximately 50 percent of men, while doses less than this are less likely to result in long-term impaired fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Multiagent regimens associated with infertility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Procarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     Procarbazine",
"    </a>",
"    is rarely used as a single agent in the treatment of cancer, except perhaps in the setting of high grade brain tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .) Data from non-human primates indicate that it is extremely toxic to the germinal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/39\">",
"     39",
"    </a>",
"    ]. As deduced from its effects when used in combination therapy for Hodgkin lymphoma (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Hodgkin lymphoma'",
"    </a>",
"    above), procarbazine is also very gonadotoxic in the human [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other nonalkylating cytotoxic agents that have a modest but reversible effect on sperm production include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/41\">",
"     41",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/42\">",
"     42",
"    </a>",
"    ], 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/43\">",
"     43",
"    </a>",
"    ], and the taxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The effect of chemotherapeutic agents on sperm production is dependent on when sperm counts are assessed. Even cytotoxic agents that have not been shown to affect long-term fertility, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/44\">",
"     44",
"    </a>",
"    ], can suppress spermatogenesis in the short term. There is also a report of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    negatively affecting sperm counts and motility that did not recover in every patient even after cessation of the agent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer targeted therapies such as antibodies and tyrosine kinase antagonists would be expected to have relatively minimal effect on fertility. However, there are reports of oligospermia in a patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/46\">",
"     46",
"    </a>",
"    ] even though this agent did not affect spermatogenesis in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, rapid but reversible reduction in serum testosterone concentrations has been observed in one study of men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    for non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link&amp;anchor=H272520708#H272520708\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormonal therapies used to treat prostate cancer are not cytotoxic in the same sense as are chemotherapeutic agents. However, these agents can have dramatic effects of fertility and erectile function by affecting testosterone levels or androgen signaling pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MULTIAGENT REGIMENS ASSOCIATED WITH INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the chemotherapeutic regimens known to cause infertility in men, the best studied are those used for the treatment of testicular cancer and Hodgkin lymphoma, malignancies that often affect young men, for whom fertility is an important issue. When evaluating the effects of combination therapy in men with these malignancies, it is important to bear in mind that a significant number have a preexisting reduction in sperm counts prior to any therapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Impact of cancer on gonadal function'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cisplatin and testicular cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the high frequency of gonadal dysfunction prior to any treatment, men who receive chemotherapy for testicular cancer usually undergo further deterioration in testicular function compared with those treated with orchiectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. The number of chemotherapy courses is an important variable. Men who receive more than four cycles of platinum-based chemotherapy (ie, greater than 400",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    or a cumulative dose &gt;850 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) have a 50 percent chance of irreversible impairment of spermatogenesis and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important issue is the age of the patient when receiving chemotherapy. In one study, patients treated with a high dose salvage regimen that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    had a significantly different outcome with respect to potential fertility issues based on their age at treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/50\">",
"     50",
"    </a>",
"    ]. Nonazoospermic patients averaged 28.2 years old and azoospermic patients averaged 36.2 years old. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Spermatogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of stage I nonseminomatous germ cell tumors\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men treated for Hodgkin lymphoma, administration of six or more courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (MOPP), or mechlorethamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , procarbazine, and prednisolone (MVPP) results in azoospermia in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. In contrast, the alternative ABVD regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , vinblastine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) is significantly less gonadotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In one study, as an example, azoospermia and oligospermia developed in 36 and 20 percent of men treated with ABVD, respectively, and all recovered to normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/53\">",
"     53",
"    </a>",
"    ]. In contrast, 97 percent of men treated with MOPP became azoospermic, with recovery of spermatogenesis in only three of 21 men retested during follow-up. This difference in long-term fertility outcome is one of the reasons why ABVD is usually chosen over MOPP as initial therapy for advanced Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to this regimen would not be expected to negatively affect the effects of CHOP on sperm production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, chemotherapy regimens used for the treatment of non-Hodgkin lymphoma (NHL) tend to be less gonadotoxic than those used for Hodgkin lymphoma. In a study of 71 men with NHL who received CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) chemotherapy, all became azoospermic during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/10\">",
"     10",
"    </a>",
"    ]. By five years following chemotherapy, sperm counts had returned to normal or to the oligospermic range in 67 and 5 percent of men, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much of the reduction in long-term gonadal toxicity in men treated for NHL has been attributed to the avoidance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    . In one study that compared the incidence of long-term gonadal toxicity in relapse-free survivors of high-grade NHL with those treated for Hodgkin lymphoma, gonadal dysfunction (as assessed by elevated FSH levels) was twice as frequent in men with Hodgkin lymphoma (65 versus 32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/40\">",
"     40",
"    </a>",
"    ]. A comparison of the chemotherapy regimens used in the two groups demonstrated comparable cumulative doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , but men treated for Hodgkin lymphoma received a median cumulative procarbazine dose of 13.3 g per patient.",
"   </p>",
"   <p>",
"    This hypothesis is further supported by the fact that other chemotherapy regimens for NHL that do not include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , eg, VAPEC-B (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/56\">",
"     56",
"    </a>",
"    ] or MACOP-B (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , vincristine, cyclophosphamide, and bleomycin) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/57\">",
"     57",
"    </a>",
"    ], also tend to be less gonadotoxic. Spermatogenesis recovers in almost all patients treated with these regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the greater degree of myelosuppression, the chemotherapeutic regimens that are used to treat acute leukemia appear to be associated with less long-term gonadal toxicity than those used to treat lymphoma, even when prolonged maintenance therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. This was illustrated in a study of 10 men with acute lymphoblastic or undifferentiated leukemia, in whom azoospermia and elevated FSH levels were observed in all after completion of induction and consolidation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/58\">",
"     58",
"    </a>",
"    ]. However, in all subjects, recovery of spermatogenesis (as indicated by normalization of FSH levels and sperm counts) occurred in the second year of maintenance therapy.",
"   </p>",
"   <p>",
"    There are other reports of patients being treated with AML regimens who have had long term abnormalities in sperm count or motility; however, in this study the two affected patients were 55 years old and 59 years old, and therefore the impact on possible infertility is likely to be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadal damage is an invariable consequence of the high-dose myeloablative chemotherapy used for autologous or allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Such patients are at a higher risk for long-term infertility than those receiving chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/64\">",
"     64",
"    </a>",
"    ]. While the majority of women undergoing high dose chemotherapy with hematopoietic cell transplantation are rendered permanently infertile, particularly if treated after the age of 25, recovery of gonadal function tends to occur more often in men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF DRUG-INDUCED INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of gonadal function in a male patient who has received cytotoxic chemotherapy should include a physical examination, semen analysis, and hormonal evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that approximately three-quarters of the volume of the testis is made up of seminiferous tubules, physical examination of men who have received gonadotoxic chemotherapy will typically demonstrate a significant decrease in testicular volume. Testicular size is most easily assessed with a Prader orchidometer; in normal men it ranges from 15 to 25 mL. Regression of secondary sexual characteristics or symptoms of sexual dysfunction (such as decreased libido and potency) are rare given the low incidence of subnormal serum testosterone concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Semen analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A semen analysis is the simplest and most reliable method of assessing the impact of chemotherapy on fertility. In an effort to standardize the procedure for semen collection and analysis, the WHO published the Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus interaction, which was last revised in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/69\">",
"     69",
"    </a>",
"    ]. Semen analysis is very sensitive to the duration of abstinence prior to collection. Therefore, it is recommended that a sample be collected after a minimum of 48 hours and not longer than seven days abstinence.",
"   </p>",
"   <p>",
"    The lower reference limits for normal sperm concentration used to be &gt;20 x",
"    <span class=\"nowrap\">",
"     10(6)/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/70\">",
"     70",
"    </a>",
"    ]. Current reference limits for semen analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/69\">",
"     69",
"    </a>",
"    ], as revised and published by the World Health Organization (WHO), include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of male infertility\", section on 'Standard semen analysis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sperm concentration &mdash; 15 million",
"      <span class=\"nowrap\">",
"       spermatozoa/mL",
"      </span>",
"      (95% CI 12-16)",
"     </li>",
"     <li>",
"      Total sperm number&mdash; 39 million spermatozoa per ejaculate (95% CI 33-46)",
"     </li>",
"     <li>",
"      Morphology &mdash; 4 percent normal forms (95% CI 3-4), using \"strict\" Tygerberg method [",
"      <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vitality &mdash; 58 percent live (95% CI 55-63)",
"     </li>",
"     <li>",
"      Progressive motility &mdash; 32 percent (95% CI 31-34)",
"     </li>",
"     <li>",
"      Total (progressive + nonprogressive motility) &mdash; 40 percent (95% CI 38-42)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sperm concentration has traditionally been accepted as the most important determinant of fertility. However, because of the large intersample variability in sperm concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/72\">",
"     72",
"    </a>",
"    ], a diagnosis of male infertility should never be based on a single sample. If the first sample gives an abnormal result, two more samples should be obtained several weeks apart to permit adequate interpretation. When assessing fertility potential in men who have received chemotherapy, it is important to keep in mind that recovery of spermatogenesis may continue for up to five years after completing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hormonal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory assessment should include measurement of serum FSH, LH, and testosterone levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of male hypogonadism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     FSH and inhibin B levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSH is a very sensitive hormonal indicator of seminiferous tubular damage; the serum FSH concentration may be increased five- to 10-fold in men who have received cytotoxic chemotherapy. The mechanism of the increase is a decrease in the peptide hormone, inhibin B, which is secreted by Sertoli cells and inhibits FSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. In a prospective study of 12 men with hematologic malignancies treated with combination chemotherapy, inhibin B levels fell to 20 percent of baseline and FSH rose fivefold over baseline within four months of beginning treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibin B may be superior to FSH as a marker for spermatogenesis in survivors of childhood cancer. In a study of 56 males who had received combination chemotherapy with ABVD or EBVD with or without MOPP for non-Hodgkin lymphoma, patients who received MOPP had higher FSH levels (16.8 versus 3.0",
"    <span class=\"nowrap\">",
"     U/L),",
"    </span>",
"    lower inhibin B levels (17.5 versus 143",
"    <span class=\"nowrap\">",
"     ng/L),",
"    </span>",
"    and lower sperm counts (1.1 versus 49.5 x",
"    <span class=\"nowrap\">",
"     10(6)/mL)",
"    </span>",
"    than those treated without MOPP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/79\">",
"     79",
"    </a>",
"    ]. However, only inhibin B showed an independent correlation with sperm concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     LH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo, LH secretion is pulsatile, so a single LH measurement may be misleading and should always be interpreted in the context of a concomitant serum testosterone level. LH levels are typically normal or slightly elevated following cytotoxic chemotherapy, while testosterone levels tend to remain in the lower end of the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Total testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total, rather than free, testosterone should be measured, since chemotherapy does not affect levels of the binding protein for testosterone, sex hormone binding globulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Testicular biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for a diagnostic testicular biopsy in the evaluation of gonadal dysfunction secondary to cytotoxic agents. However, if no sperm are present in the ejaculate, and fertility is desired, it may be possible to retrieve sperm by testicular aspiration or biopsy, which can then be used for intracytoplasmic sperm injection (ICSI). Although successful pregnancies have been reported in men with chemotherapy-induced azoospermia using this technique, a diagnostic biopsy was of only limited value in predicting the outcome of sperm retrieval [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of male infertility\", section on 'Retrieval of sperm from the testis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H34\">",
"     'Semen cryopreservation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An increased frequency of aneuploidy in sperm has been reported in some [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/83\">",
"     83",
"    </a>",
"    ] following chemotherapy. However, to date there has been no reported increase in genetically-mediated birth defects in children fathered by men who have had cytotoxic chemotherapy, perhaps due to selection bias against genetically abnormal sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/84\">",
"     84",
"    </a>",
"    ]. However, ICSI may overcome nature's barrier to transmitting genetic diseases, in that by manipulating gametes, the natural sperm selection process is entirely overridden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PREVENTION OF GONADAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As treatment for cancer has become more successful during the last few decades, increasing attention must now be focused on improving quality of life in these patients. Sexual function and fertility have been reported to be the major lifestyle concerns in more than 80 percent of men who are long-term survivors of cancer chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/85\">",
"     85",
"    </a>",
"    ]. Given the deleterious effects of chemotherapy on the testis, a number of strategies have been explored to preserve fertility in men scheduled to receive cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Semen cryopreservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest strategy for preserving fertility is to obtain a semen sample for cryostorage prior to initiating therapy. However, this approach has a number of limitations. First, pretreatment semen parameters are abnormal in a significant number of patients (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Impact of cancer on gonadal function'",
"    </a>",
"    above). Second, the process of freeze-thawing has an additional negative impact on sperm function causing a further decrease in sperm motility, although this effect is no worse in cancer patients than in healthy men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/87\">",
"     87",
"    </a>",
"    ]. Third, cryopreservation is not an option for patients who are still prepubertal. Fourth, most insurance companies will not cover the monthly cost of maintaining the specimen.",
"   </p>",
"   <p>",
"    Prior to the development of assisted reproductive technologies such as IVF and ICSI, semen cryopreservation was generally not offered to men with poor baseline semen parameters, ie, sperm counts &lt;20 x",
"    <span class=\"nowrap\">",
"     106/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &lt;40 percent motile sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/88,89\">",
"     88,89",
"    </a>",
"    ], as it was presumed that such counts would be too low for conception to occur using artificial insemination. However, with the advent of IVF, viable pregnancies have been reported with as few as 500,000 motile spermatozoa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Therefore, semen cryopreservation should now be offered to all patients as long as there are some spermatozoa present in the ejaculate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of male infertility\", section on 'Intracytoplasmic sperm injection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All men scheduled for potentially gonadotoxic chemotherapy who are interested in future paternity should be informed about the risk of infertility and referred for sperm banking. However, only 50 percent are offered sperm banking, and even fewer result in cryopreserved sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/95\">",
"     95",
"    </a>",
"    ], in spite of current guidelines from the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/96\">",
"     96",
"    </a>",
"    ]. In the past, men who developed azoospermia after chemotherapy were considered to be sterile. Now, many of these men (approximately 37 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/97\">",
"     97",
"    </a>",
"    ] are able to undergo successful testicular sperm extraction and intracytoplasmic sperm injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of male infertility\", section on 'Retrieval of sperm from the testis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Hormonal manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration that the prepubertal testis appears to be less susceptible to the gonadotoxic effects of chemotherapy than the mature adult testis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/5\">",
"     5",
"    </a>",
"    ] led to the hypothesis that suppression of testicular function in adult men undergoing chemotherapy might preserve their fertility. While studies in a variety of animal models, including the rat [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/98,99\">",
"     98,99",
"    </a>",
"    ] and mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/100\">",
"     100",
"    </a>",
"    ], have yielded encouraging results, the experience to date in the human has been disappointing. In rats treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , administration of the GnRH agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate, for 10 weeks prevented loss of spermatogenic cells. In this study, the percentage of seminiferous tubules with differentiating germs cells was 98 percent in the group treated with leuprolide acetate versus 20 percent in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/99\">",
"     99",
"    </a>",
"    ]. A similar beneficial effect on fertility in the rat has been reported with use of testosterone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/101\">",
"     101",
"    </a>",
"    ] and following treatment with a GnRH antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to rodent models, data on the efficacy of GnRH analogs in adult men with Hodgkin lymphoma and germ cell tumors have been disappointing. Studies using a variety of GnRH analogs to reversibly suppress steroidogenesis demonstrated no benefit in either preserving spermatogenesis or accelerating its recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. These studies generally involved small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/103,105\">",
"     103,105",
"    </a>",
"    ], and one was not placebo-controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One potential explanation for the discrepancy between the results of animal and human studies is that the mechanism of chemotherapy-induced infertility is not the same in these two models. In the rat model, chemotherapy has been shown to inhibit the ability of the surviving spermatogonia to undergo differentiation and did not lead to stem cell ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/24/13706/abstract/99\">",
"     99",
"    </a>",
"    ]. In men who receive combination chemotherapy, however, it is possible that the gonadal toxicity observed is greater than that seen after administration of a single agent in the rat; complete ablation of the germinal epithelium in this setting would preclude any possibility of recovery of spermatogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/57/11154?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As treatment for cancer has become more successful during the last few decades, increasing attention must now be focused on improving quality of life in these patients. Sexual function and fertility have been reported to be the major lifestyle concerns in more than 80 percent of men who are long-term survivors of cancer chemotherapy. We recommend the following for these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Where possible, chemotherapeutic regimens that include agents known to cause permanent gonadal dysfunction, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , should be avoided in patients wanting to preserve fertility whenever agents with at least equal efficacy but less gonadotoxicity are available. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chemotherapeutic agents associated with infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All men scheduled for potentially gonadotoxic chemotherapy who are interested in future paternity should be informed about the risk of infertility and referred for sperm banking. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Semen cryopreservation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/1\">",
"      Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/2\">",
"      Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982; 9:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/3\">",
"      Costabile RA. The effects of cancer and cancer therapy on male reproductive function. J Urol 1993; 149:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/4\">",
"      Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998; 27:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/5\">",
"      Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988; 259:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/6\">",
"      Richter P, Calamera JC, Morgenfeld MC, et al. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer 1970; 25:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/7\">",
"      Roeser HP, Stocks AE, Smith AJ. Testicular damage due to cytotoxic drugs and recovery after cessation of therapy. Aust N Z J Med 1978; 8:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/8\">",
"      Meistrich ML, Chawla SP, Da Cunha MF, et al. Recovery of sperm production after chemotherapy for osteosarcoma. Cancer 1989; 63:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/9\">",
"      Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin 1990; 40:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/10\">",
"      Pryzant RM, Meistrich ML, Wilson G, et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol 1993; 11:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/11\">",
"      Bryd&oslash;y M, Foss&aring; SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/12\">",
"      Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 1997; 68:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/13\">",
"      Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972; 1:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/14\">",
"      Meistrich ML. Relationship between spermatogonial stem cell survival and testis function after cytotoxic therapy. Br J Cancer Suppl 1986; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/15\">",
"      Bordallo MA, Guimar&atilde;es MM, Pessoa CH, et al. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence. J Pediatr Endocrinol Metab 2004; 17:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/16\">",
"      Bar-Shira Maymon B, Yogev L, Marks A, et al. Sertoli cell inactivation by cytotoxic damage to the human testis after cancer chemotherapy. Fertil Steril 2004; 81:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/17\">",
"      Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 1999; 17:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/18\">",
"      Mecklenburg RS, Sherins RJ. Gonadotropin response to luteinizing hormone-releasing hormone in men with germinal aplasia. J Clin Endocrinol Metab 1974; 38:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/19\">",
"      Howell SJ, Radford JA, Adams JE, et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 2001; 55:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/20\">",
"      De Palma A, Vicari E, Palermo I, et al. Effects of cancer and anti-neoplastic treatment on the human testicular function. J Endocrinol Invest 2000; 23:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/21\">",
"      Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA 1981; 245:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/22\">",
"      Vigersky RA, Chapman RM, Berenberg J, Glass AR. Testicular dysfunction in untreated Hodgkin's disease. Am J Med 1982; 73:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/23\">",
"      Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/24\">",
"      Carroll PR, Whitmore WF Jr, Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987; 137:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/25\">",
"      Hansen PV, Trykker H, Andersen J, Helkjaer PE. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989; 64:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/26\">",
"      Petersen PM, Skakkebaek NE, Vistisen K, et al. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/27\">",
"      Carroll PR, Whitmore WF Jr, Richardson M, et al. Testicular failure in patients with extragonadal germ cell tumors. Cancer 1987; 60:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/28\">",
"      Redman JR, Bajorunas DR, Goldstein MC, et al. Semen cryopreservation and artificial insemination for Hodgkin's disease. J Clin Oncol 1987; 5:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/29\">",
"      Scammell GE, White N, Stedronska J, et al. Cryopreservation of semen in men with testicular tumour or Hodgkin's disease: results of artificial insemination of their partners. Lancet 1985; 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/30\">",
"      Berthelsen JG, Skakkebaek NE. Gonadal function in men with testis cancer. Fertil Steril 1983; 39:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/31\">",
"      Ho GT, Gardner H, DeWolf WC, et al. Influence of testicular carcinoma on ipsilateral spermatogenesis. J Urol 1992; 148:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/32\">",
"      Calkins JH, Sigel MM, Nankin HR, Lin T. Interleukin-1 inhibits Leydig cell steroidogenesis in primary culture. Endocrinology 1988; 123:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/33\">",
"      Guo H, Calkins JH, Sigel MM, Lin T. Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. Endocrinology 1990; 127:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/34\">",
"      Hallak J, Kolettis PN, Sekhon VS, et al. Cryopreservation of sperm from patients with leukemia: is it worth the effort? Cancer 1999; 85:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/35\">",
"      Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/36\">",
"      Meistrich ML, Wilson G, Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 1992; 70:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/37\">",
"      Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18:4016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/38\">",
"      Ridola V, Fawaz O, Aubier F, et al. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens. Eur J Cancer 2009; 45:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/39\">",
"      Sieber SM, Correa P, Dalgard DW, Adamson RH. Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res 1978; 38:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/40\">",
"      Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/41\">",
"      El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/42\">",
"      Da Cunha MF, Meistrich ML, Ried HL, et al. Active sperm production after cancer chemotherapy with doxorubicin. J Urol 1983; 130:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/43\">",
"      Chatterjee R, Haines GA, Perera DM, et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000; 15:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/44\">",
"      Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/45\">",
"      Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007; 37:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/46\">",
"      Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004; 351:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/47\">",
"      Schultheis B, Nijmeijer BA, Yin H, et al. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 2012; 36:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/48\">",
"      Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012; 118:5302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/49\">",
"      Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/50\">",
"      Ishikawa T, Kamidono S, Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. Urology 2004; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/51\">",
"      Chapman RM, Sutcliffe SB, Rees LH, et al. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979; 1:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/52\">",
"      Whitehead E, Shalet SM, Blackledge G, et al. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 1982; 49:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/53\">",
"      Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/54\">",
"      Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/55\">",
"      Anselmo AP, Cartoni C, Bellantuono P, et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/56\">",
"      Radford JA, Clark S, Crowther D, Shalet SM. Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer 1994; 69:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/57\">",
"      M&uuml;ller U, Stahel RA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1993; 4:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/58\">",
"      Kreuser ED, Hetzel WD, Heit W, et al. Reproductive and endocrine gonadal functions in adults following multidrug chemotherapy for acute lymphoblastic or undifferentiated leukemia. J Clin Oncol 1988; 6:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/59\">",
"      Evenson DP, Arlin Z, Welt S, et al. Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia. Cancer 1984; 53:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/60\">",
"      Maguire LC, Dick FR, Sherman BM. The effects of anti-leukemic therapy on gonadal histology in adult males. Cancer 1981; 48:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/61\">",
"      Lemez P, Urb&aacute;nek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma 2005; 52:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/62\">",
"      Chatterjee R, Goldstone AH. Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Bone Marrow Transplant 1996; 17:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/63\">",
"      Apperley JF, Reddy N. Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev 1995; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/64\">",
"      Watson M, Wheatley K, Harrison GA, et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999; 86:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/65\">",
"      Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000; 26:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/66\">",
"      Check ML, Brown T, Check JH. Recovery of spermatogenesis and successful conception after bone marrow transplant for acute leukaemia: case report. Hum Reprod 2000; 15:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/67\">",
"      Jacob A, Barker H, Goodman A, Holmes J. Recovery of spermatogenesis following bone marrow transplantation. Bone Marrow Transplant 1998; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/68\">",
"      Rov&oacute; A, Tichelli A, Passweg JR, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 2006; 108:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/69\">",
"      Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 4th, Cambridge University Press, Cambridge UK 1999.",
"    </li>",
"    <li>",
"     World Health Organization Department of Reproductive Health and Research. World Health Organization Laboratory Manual for the Examination and Processing of Human Semen, 5th ed, World Health Organization, Geneva, Switzerland 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/72\">",
"      Schwartz D, Laplanche A, Jouannet P, David G. Within-subject variability of human semen in regard to sperm count, volume, total number of spermatozoa and length of abstinence. J Reprod Fertil 1979; 57:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/73\">",
"      Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/74\">",
"      Illingworth PJ, Groome NP, Byrd W, et al. Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 1996; 81:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/75\">",
"      Anawalt BD, Bebb RA, Matsumoto AM, et al. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996; 81:3341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/76\">",
"      Hayes FJ, Hall JE, Boepple PA, Crowley WF Jr. Clinical review 96: Differential control of gonadotropin secretion in the human: endocrine role of inhibin. J Clin Endocrinol Metab 1998; 83:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/77\">",
"      Hayes FJ, Pitteloud N, DeCruz S, et al. Importance of inhibin B in the regulation of FSH secretion in the human male. J Clin Endocrinol Metab 2001; 86:5541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/78\">",
"      Wallace EM, Groome NP, Riley SC, et al. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. J Clin Endocrinol Metab 1997; 82:3111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/79\">",
"      van Beek RD, Smit M, van den Heuvel-Eibrink MM, et al. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood. Hum Reprod 2007; 22:3215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/80\">",
"      Chan PT, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/81\">",
"      Genesc&agrave; A, Mir&oacute; R, Caball&iacute;n MR, et al. Sperm chromosome studies in individuals treated for testicular cancer. Hum Reprod 1990; 5:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/82\">",
"      Robbins WA, Meistrich ML, Moore D, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 1997; 16:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/83\">",
"      Martin R. Human sperm chromosome complements in chemotherapy patients and infertile men. Chromosoma 1998; 107:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/84\">",
"      Senturia YD, Peckham CS, Peckham MJ. Children fathered by men treated for testicular cancer. Lancet 1985; 2:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/85\">",
"      Berthelsen JG. Testicular cancer and fertility. Int J Androl 1987; 10:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/86\">",
"      Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005; 6:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/87\">",
"      O'Connell M, McClure N, Lewis SE. The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod 2002; 17:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/88\">",
"      Sanger WG, Armitage JO, Schmidt MA. Feasibility of semen cryopreservation in patients with malignant disease. JAMA 1980; 244:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/89\">",
"      Reed E, Sanger WG, Armitage JO. Results of semen cryopreservation in young men with testicular carcinoma and lymphoma. J Clin Oncol 1986; 4:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/90\">",
"      Rowland GF, Cohen J, Steptoe PC, Hewitt J. Pregnancy following in vitro fertilization using cryopreserved semen from a man with testicular teratoma. Urology 1985; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/91\">",
"      Tournaye H, Camus M, Bollen N, et al. In vitro fertilization techniques with frozen-thawed sperm: a method for preserving the progenitive potential of Hodgkin patients. Fertil Steril 1991; 55:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/92\">",
"      Schmidt KL, Larsen E, Bangsb&oslash;ll S, et al. Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples. Hum Reprod 2004; 19:2806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/93\">",
"      Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer--criteria change. Fertil Steril 1992; 58:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/94\">",
"      Kelleher S, Wishart SM, Liu PY, et al. Long-term outcomes of elective human sperm cryostorage. Hum Reprod 2001; 16:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/95\">",
"      Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/96\">",
"      Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/97\">",
"      Hsiao W, Stahl PJ, Osterberg EC, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol 2011; 29:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/98\">",
"      Ward JA, Robinson J, Furr BJ, et al. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 1990; 50:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/99\">",
"      Meistrich ML, Wilson G, Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res 1999; 59:3557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/100\">",
"      Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/101\">",
"      Delic JI, Bush C, Peckham MJ. Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. Cancer Res 1986; 46:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/102\">",
"      Pogach LM, Lee Y, Gould S, et al. Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration. Cancer Res 1988; 48:4354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/103\">",
"      Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/104\">",
"      Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/105\">",
"      Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990; 22:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/24/13706/abstract/106\">",
"      Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction 2008; 136:691.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7455 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.80.101-607E99995B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13706=[""].join("\n");
var outline_f13_24_13706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF DRUG-INDUCED INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impact on the germinal epithelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impact on Leydig cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMPACT OF CANCER ON GONADAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Testicular cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHEMOTHERAPEUTIC AGENTS ASSOCIATED WITH INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chlorambucil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Procarbazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MULTIAGENT REGIMENS ASSOCIATED WITH INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cisplatin and testicular cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ASSESSMENT OF DRUG-INDUCED INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Semen analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hormonal evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - FSH and inhibin B levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - LH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Total testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Testicular biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PREVENTION OF GONADAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Semen cryopreservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Hormonal manipulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/57/11154?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_24_13707="Loss rate after MPR by starting and ending number";
var content_f13_24_13707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Loss rate after multifetal pregnancy reduction by starting and ending number",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Starting number of fetuses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss rate if ending as a twin gestation",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss rate if ending as a singleton gestation",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Five or more",
"       </td>",
"       <td class=\"centered\">",
"        12.1",
"       </td>",
"       <td class=\"centered\">",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four",
"       </td>",
"       <td class=\"centered\">",
"        5.8",
"       </td>",
"       <td class=\"centered\">",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three",
"       </td>",
"       <td class=\"centered\">",
"        4.5",
"       </td>",
"       <td class=\"centered\">",
"        6.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two",
"       </td>",
"       <td class=\"centered\">",
"        N/A",
"       </td>",
"       <td class=\"centered\">",
"        2.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stone J, Ferrara L, Kamrath J, et al. Contemporary outcomes with the latest 1000 cases of multifetal pregnancy reduction (MPR). Am J Obstet Gynecol 2008; 199:406.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13707=[""].join("\n");
var outline_f13_24_13707=null;
var title_f13_24_13708="ORS other bev PI";
var content_f13_24_13708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of oral rehydration solutions (ORS) to other beverages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        mEq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Carbohydrate (g/L)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sodium",
"       </td>",
"       <td class=\"subtitle2\">",
"        Potassium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        ORT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CeraLyte&reg;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enfalyte&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pedialyte&reg;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rehydralyte&reg;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other Beverages (not appropriate for rehydration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple juice",
"       </td>",
"       <td>",
"        100-150",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chicken broth",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colas",
"       </td>",
"       <td>",
"        100-150",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gatorade&reg;",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginger Ale",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tea",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13708=[""].join("\n");
var outline_f13_24_13708=null;
var title_f13_24_13709="Felodipine in HF V HeFT";
var content_f13_24_13709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Felodipine does not affect mortality in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 176px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In V-HeFT III, felodipine SR or placebo was randomly administered to 450 patients with chronic heart failure receiving optimal therapy with enalapril and diuretics. Mortality (13.8 versus 12.8 percent) did not differ significantly between the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cohen JN, Ziesche S, Smith R, et al, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Circulation 1997; 96:856.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13709=[""].join("\n");
var outline_f13_24_13709=null;
var title_f13_24_13710="Contents: Bipolar disorders";
var content_f13_24_13710=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bipolar disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bipolar disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43065\">",
"           Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19639\">",
"           Bipolar disorder in adults: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27802\">",
"           Bipolar disorder in adults: Maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44088\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38026\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/61/11226\">",
"           Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37417\">",
"           Bipolar disorder in adults: Treating major depression with antidepressants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/52/8009\">",
"           Bipolar disorder in adults: Treating major depression with second-generation antipsychotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27129\">",
"           Bipolar disorder in postpartum women: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/1/5146\">",
"           Bipolar disorder in postpartum women: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/22/38248\">",
"           Bipolar disorder in pregnant women: Treatment of major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4362\">",
"           Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/24/40329\">",
"           Bipolar disorder in women: Contraception and preconception assessment and counseling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25638\">",
"           Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/51/2874\">",
"           Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16330\">",
"           Geriatric bipolar disorder: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7545\">",
"           Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22601\">",
"           Geriatric bipolar disorder: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42216\">",
"           Rapid cycling bipolar disorder in adults: Treatment of major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41673\">",
"           Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31497\">",
"           Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F00C1840BF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_24_13710=[""].join("\n");
var outline_f13_24_13710=null;
var title_f13_24_13711="Systemic onset JIA rash";
var content_f13_24_13711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systemic onset juvenile idiopathic arthritis rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 250px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD6AV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzfTEbzRwfeuqgO1ACvy4qYaNDZhWSQMDyPUUSKHG1OMd6wbaNUrlC6AhZTGeT3akedCuD+tV9SyikHPHf1rlb/V/KyNwBrOzb0L23N2/lj8pgSMVR0PWDHHc2s8u5UbchJ7elcXqWvO2UgJLHv6VmW11dIzsDln7mt40nbUzdRX0PQr7WI+RurkdX1UtLiGTDZ6g9KzGW5nP7xz+FOjsB3q4wjHclycti4utOkeHkaRu1Y7NNLI7nOXOTWrHZAdhU62oHaq54x2Dkk9zCW2lbtUi2cjVux2xY4Rcn2Ga0rPQr+6IEFrIc98YFS66RSoNnKrYN3NSLYZPIr0Sx8AanOA0oEQ/Ot6z+GbkAyOxP0qPbmiw55Eunp3XNTR2SDomfwr3Sz+GMRHzoQa3LT4bWiKD5SZB6EVm67LVCKPnhLM/wRn8FqdNPnPSB/wAq+j18C2cRB8pffFX4vCWmxAEW4Y+p7Vm6zZapJHzRHpN5JwkDk+y1o2fg/W7wjybGU+5GK+lrfSbaEfuYIl9Tsq4lqFwwAA/u4pe0kWqcex4Fpvwm1m4w11LBboefU11Wm/CLT4NrX1zJOe+DgV6v5HXpzTWiOMcEVm5sailscjY+BtDs1G2wRj6tzWtFo1jb/wCptYk+i1s8AbWHX1qKWPdyqHJ6DNK7HuUEhjUYEZH0FDQBmGBx7npVyKJ2JBOOcVYa2wQcFvxoC1jPaLjAHHr6U77OPr/SrvkA85xTXj2/c2E0CsZ0luA5UqSTTBFLA26CWRG/2WxWhLkEZ6UmwMRtbGaWwrFGS81FVwzCVR/eHP51GmrtE+JIAD9a0GTC4Oap3NuroQQPyrRVZrqQ6cX0JodbhJ+cMp9xmrcepwvkrKp/HFczPaFTxkVUfeGOVP1XrWixM1uT7FHbpdbjkEEDrzUiXAXpXFQy55R2U+xxVhb27iI2zZx2cZFaLFLqiHRfQ7IXJJGM/wCFTJLnqcVx0WszpgyQKw/2TjNXYfENv/y1jkQ/TIrRV4PqQ6Ul0OtibHpk1MJRgDNc7BrlnIMLcoCf4W4rRt50mB8uRWH+yc1qpxezM3Frc0g/PrSSyYjYIRvx8v1qqz7R/SopJ2yRxVORJycusMby4t7r93NHzz0rH1G4uZbRbu0gM8e4qSp5H4U3xVJHLqcrQctjaz/zFa/w7P2yG6sGcCSIh0BGcg9a5FSUpu/Url6ngR17XtEiEOqWrXsS/dkHDY96yJfiBdifKWqpH3UtzXvl3pFrKjK8I54Jx1rldR+HWkXz7pbdo2/vR8VnGcftI6ZU39lnl9x4z+1wMPJYSY4rmnS61CYuyuQeyivcbf4X6JCQcTt/vNW9ZeCNKt1XZHgehq1VjH4UL2Tl8TPn+10K4YA+SVHvWpb+HbluiHHqRivoKDwxYx8Ko59F5q5b+HLJW+ePdjsTUOtJlKlFHz1H4cuCcKjO3ogrY0/wLq94cQ2hRf7zCvoW002ygAENtGvvtrUjCKoIA29sCp5myuVLZHh2nfCW5fab2YKDyQorpbP4VabFgyK8pH988V6fEysTtC1IwGCCTj27UuYtKxyGm+CNMtiBHbQq3fArZj0K1iYYRVA4rWihEakg5HXJpwjDryMqfelcqxSj02GM8KD9O9WvJjjUFEQH3qWNeygjFJjLlBk/rilcdiIAqdwXHqKcPmxkYqdePlKgmn+VjBGMk0mKxTKkt0GPY9aZty2MdecYq6F+8MjIpcZUZH04pAVNp2nYQD3zTVj3DLcHtU5XdnBORUR+Xordfyp2GiMIFPJJNKy5GVPy090B5U5A9aQxgnHJA7UgIVj3YKrkj2p7R7+vG2pwrIwBUsKeo3fwZ7+1AMiSHAGefpQIASdvyn0NOeRUO05XPejz49wXcev4UByshki2knqfaozGSoIGSO1aOwEY4z1zULhQSvcdhzSuBSni3jlePQ1CkIxhABjoK0pELDgkMO+KRYfl3MB/KgRmnCsPMjx9Oaa8CuMp+VX2hHB/WoGjw/GFPt0qhOxm3EDj7wBXFZssS+nNdDJz26HFVJogw5GD60mriOda2VzxwaaYpI+wZR61pzwhT0PPfFRKpwMj8PWlZjKTAnoOKRl55Xn6Vekjx0GD9KQKSCCtKwjOKIeCoK0eUFYGMup/2TVswd9uaa0RwMr+NAMamo6hbEFLlyo7P81T3GvXklu0bogZh/rFqs0Zzznj1HFROgbHI54xirjUlHqQ4RfQouFYHrk81Ba3lxpl4Lq0bbJgr17VpqgHsPSqmpael9FlC0cgPDKcVoqrIcEdgbTJBKjIpJLbg8fnxWy0W9Bxj60ww5BUY57ioZqzEFqRgkYNOWEAj5BkdeK2DAqnHH5Uwxg84yPT0oBMqBRwMdqfGpDHOD9KtmMAD5c+1PEI/wB0UAVmIHGOoqSFSB1JB7U6VBge3tUirmNSpJ/nQCQ8IjDlfmqQEICG4PtTU3YGOSOxpJ1LxZddq55AplpXLCGMjBB2/lSmAbgyuAg5wKrwW3mKNpbaemasm1lJwhwB1pDtbqSqFUbv60gwM7ScdzT3jKjHBxUbxbm2jhcc9qVhoVYwMnO4nnmhN4bk7/QEdKbAAkojlU5PRs9auMgzgk4607hsQiLcN2BzRt2Ke9EpMYTYCcnrntUku7ywI2AduMkVIyBvmPBwO/FQmA+YSckH1q2kbBfn5PqOKXahZSSc+lF2Bnqp37XTPHBz1p8UQVj5ZOOuM5rRkhU4KgYz3FRAIrFSoDE5BFF7gQAOXKFvccUpBPylcgd6lm8xNpjAOevHNNiLFWOAD2wOtA7dSC4QMgzwBUf2eLIc8nsKsx7myeOeCelPWA8kZIx3oFqivny1O7IU9CBT1A5J+bPOaeqsowVz9OKaHBDfKQy9RSCw1GViwTqOoNMaQMSY8kjqMURHe+/37dKsFEHIXB9u9AOyKxjDgcbc81D5YL+mP1q6TkN09h6VWMRdTtfBPeqRHUgkiBz6D0qvNEGAyOexFX0DKCHOcd8daZIo65yD37CmIxriJhwDjH61SkjAyFwD3FbV1EGB2kVnSRLkkjDUmIphBnnk05FznOPqB0qTbzwTSIGLHaPrSAjK4OFwfcUhXK5IPvirBXBznn1qNY2EwZePwpIEV/IDJnIOaia3A7HmtTaCPulT6DvQ0Wc5xRYRiNE245HH0pBbOfuk89q2Db5INQXtrIYGFqf3vb86aJZ1bxb2ByQBxTlhXPH4GpwgCk9D606NMJk855AxVjuVniAyxORTPLXHX8+1XHUbiTkGoSvzE+lSBAowRgH8qkYHaMKKevzbsDBHHFOVWBwFJB655p2GyAgZ+cfjTkjDZGCPSrDhQM44HXihNxf5VOPcUDRVHDY2A4PWrkKLkjAIPXFLFABn5ec9SelOQBMqM+3NIocE2RtnkjpiogjTBZNzKf0qZVYjjlTxmnBMjGT+BptAnYXySQA2SRTSwxgYYirCsc8cjHQVBHCPP3DOTwRnikNeY0qG9KWI5cIWU469jU0dvgnryeaII1WQlsEngE96Q7jHjyMDAXoOKYI1GcHgcVZYFSR0H1p6KHiJLEH17UAVIkblNzMeuSKdEvzFHVgSe4q2IVZwc4YdxUj8ZIHHc0DuV5TGOMYI6e9VPLUzAqcMO3rV2RQQB2PQio4LdVZsA59zTDYY4wuVIDZ4pqo7hsKBjknFTOp8zaTxjj3oU7RzjIPY9qQFYRbWyRx3p0bh5NnYCpjuAJABpqLglgASaQAyfKNnXPfvTXWLkk49cCnuWJYBQMDg0w7DHk4JPX2NOwnoVZESM/KuPpULbgAD+eKssxZiGPTrQAGXOflPTmnsIiiQ45+6R0pJI1AVunepXyCSDgCoyXC5X589R6UgsRnbhiCcfWo3H7o7QSfSpECxqcDHfFMcgoRgLxkGmJlKdPkG75c/zrPYlZB8ucjg1euJMA7sHA5/xqksgfouCD60CaZE0Y/M96I02Ekn2/CrPBByfwqNhkYJGfp1pE2Iyny5Az7E0wZxkDG3sasJggZGCetJKpZGCHDds0hiIMj/ABp2DkBwMeopkAk2/vFAx0x0qZojjPT1FACFVKjHX0o8sEZJUD1qWNBjNTRxEj5QP5UXE0awKkgHkntnoaejbGOOM9M1ThkOMsckccU/OS3zEVqSWGbc5BP5UwH584zimhiBtZgR6jvUuVbBb6gUrjGJjkL36gdqcqkBlDYI6UzyxGGOOSc4Jp0MgZMknrQx26j1UbcEgMeetPjj9CT/AFpizMJCABt6A46U6RhAnqf50i0uhLIrA5zkY6DrUKnzDhlIx0xViJ1O0kY7kdqHIZhhNo/nRYNhsKspHy49fpUzBQxOQD6560JHhCASdx9aguY8xlTn2PegCUgAhgQO5FOypUmNRn271DCv7rYcc8GpkzGwXnHpmgBY94zn7x7AUuMOGxlgeCajyWkBVvkHr0qwBvlI7Y6Y60rFEgQbcsBnP40rooTGR68Um0gDoeevpUjFeA2N2KBEWwIo59vrQRnPoOMGlLHHzhT68daY2fvA/LnPSkMc0YbkHGO+KiIZcgD6cdacGG5t25cYP1pZnCRZf16mgEUZC/mYfgE4OKtLGko4IIxjBqtcReaFaN8sB1NWYPuqS2SOOB3p2Lb0GrF5YwRhc45NEieUQo5BOQRRcybEA289/wDGoFuU37QfvfzpCs2SiYH7uM+tRHLtwOSO3pSTKV+bgL3A5pYXUBguT6ikTYYUTG0dCOfWkWIIDycdh6Uk6kSBwWBHTinxruwCRzTGI+T0GR7VCzBM9gPTip9wUkHn1JNV3UNv3EEHp7UWERzMM446cmoJOmR0FPZAqEIePX1qGRwDtGM44BpklK5iBVyBk46etZtpEySHOd3cH0raYHy+QCcfnVSMEgswwPTGCKB3dhuQuCaaRlsgg048HDEHPTimbwCexHtSIF/hz0Of0pwyqHjOOuKTHrT8bQRyOOc0hCbcH+6SKlTjoTnP1xUSbSjDqB61IiHaWGPYUDJBuyCMcetOUtuJJOKZbssp5BDdMEVdC7Tkc4GDQD0Kq/K4zwCe9WlJYYyDVBG57E+lSM/ZTgnvWrJ3LmcHIAzUqyYGMAHHrmqgfpkgsfelMu0jdnPrSHYsSMZWjOMAf3Tzipi4A5HygfSqfnFCAPuk8gdqlJyDzjP6UDuWrcq6hk+Xd2p7puAHTAzx3rP8x4gEA7fe61cjlJhBJzigq3UmiIP+99Kk68jqPyNViQSCpOP0NQyzyxxk7QuD654oGlc1o3CgZByehHT8ajZt8gAzx361Vt7hpEGcZxx/+qpI2+fByD35xmjYTRZGNw7A9SBQqYD55GO3eoiwRsMePTsaRb5ZCyA4J4GaQ0mPU7XXcNo7DHBq0W2LkkD61U8jzo08zO9T2OKmdDsOcBB05NAOw8S/Owz89VlLqp3tkZ4JNStkgbM8jr1qLzlBAxnjJ7UAhybxw53L2Ipys2SeT2+lCMAARjnsKdESrMzgBRwBnrSGIFz99T/jTpFRl2SBthIwKcxBXIAwR1AxUF3dmII2wFOmelAJNsnCeXF8+Aq8Ae1RRygyjYAMDjPami6Sb5TkHGeKry4ySh3YPbrQO3clvGJh6ncDwPWqUMYcliAuaszqJYtvc+tV7ffuZWJG3gHHWgpbFkFosDbu77jTocsC2BuPHpiqN6kqRL5ZbHrmpbGQmHBU7hQxW0uTyRsk3DjGMEetNdOGG7g08uMZOD60yRx24ApCZDcMsaLu5J45pnO1SpXaeeetJMA7qrAkD+LNL5bDLJnA7E1QitKrGcMrYwORiqwhBaRiSc+9XmGSCeT1P1quUC5c53Hp6UhXGuvIOTiqJG6RlYFT0zV9SCDt5J/Sq8qqH3nhulArlLdulKEHKimsB0zinTkZO0496g3fMQRyORSZDLUYy+VOOOVqYqSpx0PWoYclQSMd6mEhwPn69u1A0JEMtjAye1WFVVHQg/SqxRVYlc5+tPSU4CnpSGW4/lw2MHHSrcY+XDcDtVFJvug5/GrkTDOAePrQJnPgkHIJ9xmpfNJ6nIqoHywGevSkLt6dK1ILpcsQEIUd6kR8kORytUVkPcEehHepY2I5GCW7d6RdzSVgy/KwHORmnI565ye+Kz3clPkOWH6U5JcHAbnp9fegDS3Lu/eDrxj1oaQomR0HY9BVVX3YJ6Uy4lYooXjB6HvQUkaVrOWi3BlU4zQbyNiRk7ehIqlDMGIAwR0ptxGQPlAyPcUFK19S/DNGMlHJzxtz3q2X6AAYI4Oax7aIJ8xOXbrmrH2jy5sFhhhj60hPfQtzrvAKNgjiolilWboDzn2psXyOzZyTz16VY8zLds4yRjmgrm7F6GRmjBxhR2qQv6P16+tZ/nBVAx8x7Hin5ydxOSccn/PFBJYR9q45wB8ozUBISVjgEnngc0jPgk4yaYD5nGME9xS3BFsY6nr271Ijsjjcc5+7xVJZDAgLcv0wM1IJN44OVPOD2osMtyykpwPmHrTHAliCvjn3zmqss3kOmTuDdQKV5MtuPAJ9aNg2GN5cMqoy/ePWrDbQV9McmonZGkXk9ew4pkrhlwGYe3Shj3HyzbYiQpx6mkjCPEOT/ewOP1obAiyyjPYYog37cP1PI9PwoH0JGKthcJgkCmuowcHaR0wOKd8qruOBxULFmUgEbT0A5oEQxJKuWZh7+tPyQM8kk80MxWP5W46ciqkgwQ7t8wPagG7kt1Nswwxxx9Kljk3wgg/LVUkTIdpP0Paltw3l7WOSeMihB0HbX3cgAHrg9KbLIqRnfwDxUmRtxnge9ROAc5AwOeeeaCCAEqpCjAJ4z1NVZmwwz1qWdsHLNznj2qtK4ZSwOCvFIRUnbc4wSAPTjmnp2Axk96r5wcg4JOMetOjQqx5O3r9KGSTqx245x2NSL8wxk+4FCAYyCPoTTo1Kk5IJ9hSGP3EfeNOTgDaBz70jY6MP0pMjO4HHbpQMnUkHaOlSo204yeeajHABByO/vShvkwM4+lNAzBwNwZiMjvSs+RwMnPemk5HOM0xzym4rgdM8VrYhEpcqT3Pt0NPjn5OQc+tV2fIyB8v86Y4LlSrYA6g1Iy0rvvJ3KVx0qQvkDYf6VRU7SDngegqRJApG35s9M0AXklCkgnk+x5pzt5i+mOeKpGYAg5xUMFyFmwTxmguNy/A7rMTk7ccnNW1uI+WJGR2rHEp845Bwe+M/rTgU3FcH5vbvQXozWW8XIwwDA9BzUzqXKlAdwP1rJt4yH3Ma0YpBjkDFK4m10LLORwD7880Wdy5dwVJxwDVWWVVUlecdqbZ3RmJBBXHoaNx20NjeXIIJX68ikmuTDhsA9sVVDgEY5B609yGOWPA/QUmQi0swIHPH1wad5oVuWOfaq8TKQAvT9adKSF464wMGgZKsu5yzAjtgn9aepwuMjBPTGaxEllWQ/exjkGrcFwxAM3B9DRa5TVi+8qqGMmS3XJ54pi3LE56Kfu1GZdx+QjHv1qCKZvtBUKOP1oBamnG24HJx7dD+NDkEDgk/SqUQbe23Lc9xTpJCjKPX73PAoBIuK7ZG4ZI7inBsnrj6jpUa8x5H16YqOWYrDnDZHbtSES5AYkNxUM8qo+SRn0Bqu9yGlKYIAHcVDPt7kcc8mnYCeW4MaE5Bz270xyJV2ggAjpVVHXdhT8x61LHsVBhRgdTQGwoIiG1G+me9WPN25Y+nQdqrKAQDgkZqRmBwDzj0oExVmzHx6+mP1qGaUbMA496ZM5BbIG3HHqPeqN3Nj/V85OPTigQ+ecbAQcduaqzElj+fFVRO5bDn6UxZhuPQAnr0pCkSg568jvU9uGLZ42npmqqvjPO0VZhAABJ49KbEXBjGSOfampJ5nCkAjrmmeYduNvHrmopJCHwh/T+tIC6Hxyc496aCDkHr2qEMpHJ5Pp3pjOqnIJ3HvSFcsrIc44/OpkkYEhwcf3u1VIgA2R1NS7iW680AYxkz2/KopmVkxknHaq3nENjJ45/ClkmOw4yAfStLiJwxYnBzjjFCuTnHOO9UhKcZJ/pSmX5cjGaBloT7CVJzx+FNaZSwzt+ucVWchxtyeefpUcg3KNo+boCaVxluWcgrsPGeSKYxaMqwGS3PNQRbxkPgAd6nSbeWDdv88UXGnYvI7PCrZ2nvigSSRfMcc8jiooyqr8xAz271I2HTgkjFPUakWLW8LHDEjnmrolBQY61gtG6Y2AYz82e9S2jM0rfMRjsDmluU0t0azOhkyxOW6rnrT45FSM4Uhqrb12/K2WzTZH3KWkHI79KQk7mkknIAJYkdDUyygDHI/lWStwQBjG3oD6mplmDLnBJ96LBZo095K5H3hwQOOKdvOAHIGDxVHzHIXYoHcnrxUoc8ZOR2oAmLndyB7HFLJ83LckdDVVpQW8v+KnCXBPAyPWkMkt5ZN53AnHtVqDDjcVwTwRiqivhARz685qZZVKliQB6iq3Bu5dG0vtwc+/SiQsZwGHGMHAqtHIFfcOf5VK0pPzA46jHrSHsTbtmQfmU+nUVCztlTjI9D3qFpcodx5HrVYys3IHA9O1BJZkk3uTgZHpxiq8nzYHGAeahkmKnO5QPc80gcMBznHPrRcCVI1WV25Oal83dgL+vGKh3Lje2Mk46nmlEi7wi8H+VMLj9zLMV3fLjpnvTXfIJbt6nmmO43Egg9+KqSShmON3ocGkJsWS4OSwPyY71VnlHJJyMccUjv8u3n+dULmQpHweckUr2ERPciQhgT16dM08MCAd3fPNUHctwCM9Ac9akRnV8D5sVINGtEc8HnvxVrA2Hgtn3qhbKAMqPqam8wIODkDtVCLQkBj2nn0GarNKMNjIzUBud7cZqMEAk/zouC0L8MgRM5J9jTjIHbjFURKWjxz+XFPV9igZzj070hFyJmXheMHOPWnGY4wMA57VSEp5xxTpJWVMqvPpimPdnLNqAHAHTpg1JHecckA+5rkIdQ8wjmrkd0SvBBA9uRVEXOmWcMOoIxSCQdNxrGgmbjHJ61bjfOctx6HrQM01IC5z+dSxtzlSSD19qz42JIAI9iauRtyCfyosBaCqww2cGnKgCgAk0xMAY5yfWnls4Uce9Axjq2cLxjv1qeB3BGRuGKYqkR7TyexqVcKATg/oaB3FldsEhT+PQVCkoU4UFXYVYLh12n7w5xUDxFgWA5HRietBUZdCW1kYyMD+JNWpchN5OV6GqaDDcn5x6Gpo2cEhwWB96B31Hq0ciKAGUDnnpVjzFjGWJ681EpVY+FFQXLscMh57gGmF7s1o5CV4wBjtTd5LLuZiAc+hrMN2I9igMSaubzjdk5qbC2LDsskgbPIHGf5U9JSApccHrjmqhb5Q7EYBqVG+YHPyn1oBMtvMSyAJwe9Oky42hsE8dKapXgjqR3pISQ75JIx3NFxp9SW3Xy9wEhbPGKmaT5RjPHWoGkyFPPpVeW5U9/lBxRYG29SaeVS3OTjtUEkwIAGSPTFU5Lkbtveo1ctJ2HcA0WAtyr5rKcnPoanThclt2eDzVYSZbFSK6g8kkj86Yrstq2OAQeO1MYrGCx7elVWlBRiTjHeopLoEAJ07E9aBFmeQFOQR6VQkfYxAIwPxqOefKjqDVPzDnGTk0BcstNhP8ACqNzMS4wvHcmlZuCTx6GqzyDjcpznH1qWJEyqrEfKNvUjFPI38AjAPWoZZVQcEDPZqI2ITJJy3pSBmk8iogCtkVXnmwMZz361C04CdfyqhcT4LHIA6U2JFvziACT8x/KniU5Gcc1mLNv+UMc9/YVajbkc9OtAjQDDaOPy5pQ5VlzjHtVEOSeeecf/rqRHYnC0guWxLluc8+9KZxn5sgfmKphsLkn86lV8nqMd8mhMDySx3YAz/jWzCzMF3McdMVh6VOpQZwR9a6K1CMoI596r1JRaiGFBxjHPXFWk8zIORg9qiiQjOMY9O9TRnJ6A+1A0XYHLDAx+XariH5gf1/rWdGBnsD9anV2IJyG44pjsaYkzhePrU68Z7+tZ8Ug2KcEHvUscueSePagZeDKoPXOKXII3Hr71W8wdc0ecCQO3bNIRYBLZyRmgvjvnFV/PH3eDnjIpGmwDu6egHNAyeOeLcVyAakBBUkOOnGPSsmYhpMg7WHoOtXonfYMnr1oZb20LcZ/dHexOOhpJQWjARtpPWoX4XB4NR7yi43ZNO4rlhM5XkE96mjZwvJJz3qip53KD+HNTwsWySTgd/SkguTTyPhdoygq1byZChhlhzVNAMndyvXmpY5QTjKknpigq+hpZJ7gjr06Uu7AwD+J71UWVgMvkAdPSoZrgL+8BPH3VzQJItTSOR8pQEcY6VRkuNhKueD37U0XCyR7gefSqc0gyp+9jincafQtgjzNwwT61OjDJzn6E1SEqhcqRyPxquk7mUHj/GgLNm0JAwADcjr7Uecu4DqcdRVAMVGARzzx1pktxlcgjIP44pEl4yn5sEY9KqyXCkbRke+aqTXIHzHtzVU3BKlmyAfxoEXTNg8klqiMgLZ/lVRJ96grk/jjNDONwyDk+lAFzHmEd8D1pjIu/kLtHQVGki8YPP1zUdxPhCF49CaLCFd1VjnJGeQRkVG85yV6Cs6W4x0IHv3qrNcKBwc0gbL0twAFOckcZqsZmkOB684qkJCzcZK+9WIQoG7PBoJL1oSMFsD0FWfndgQwx0qmjjaOOpqdJSmXOfzpjRbEgXjOT3waesvJ3YH4VnxuNxYgg09p+Sev8qVgLnmEscDAPT3pDJtPBG39Kz/tBDAjkemOlSCXOctye3GaAZk+L/AjWDteaIQYgDJJADnb/u/4VzemaoFKhvpivoSdA8gIVGVDzlevtXk/xB8CzKZNV0aLEpJeW3XjI9QPWuutRtrE54VOjKsFx5hVlIOfSrikfeycjsK4XTNVeJtj5UjqD1FdHa34cZ3de9cuxubakMQ3ftU6OR/Q4rOhnD44GPerAlHA49uadx3Lvm5YgnpUgm7E59qqGZXAK9R696ieR8gxdM80DL7TEHLEbRzTredif3hyO1UQ2cD5QfamGU+aA2RgdqAuaYlVWbHBPNNkkzHuyoNU/My3qDQH4+U45pgmXIQXYFjkVYSXbwSdorPSU5Pz8jr7U9pgcHse9Kw3qaHnLjGTk8n6UhlBAHQHsKotJ8pCj5qrRu4k5JPvSBK5sh/mUFu3WpFf5gcn1zWcr8EnGfrzU2Qy5VePY0CRo71KHccDHJpkbhSgVst+ZqIMNoDYGR0ppEavuGfejQpMszXJOEBwDULMBwxyexzUErbslgf8KpsxPO44HGM0DvoXBKqxkKMjPfj8aS3bOeMD3qik4JChsH1qYybEyinI96BXLBYRuWdsA+gpBKxGVcEen9Kzp52OC3OOaajMRkE5HOcVRp01NWNiAzP94mo3n/8ArjpVTz8nBbtzVeWdiCBgZ9P61NjK9y1NPwQOlQSSAgKTyT61W+YkFzyOQDUh28YA3DpimFyfdhSu7HpTg/BG75j61WLEdcE015CR0oFcvmUKoUNz6iqVxcnJH61Te456gY7g1VmkLHhWHfnvQK4+ecvITkAegGKi3FiAQRjrUaoWYNkgnt6VYC8kbhn2pWEPG0cZNS/w5JwPQVECFI45x3pzPwAcn2zSsNE0U2FB5qZrrLYXj61nI25sLxinbgD/AFpjbNDzQTjOTjuajeXIXHGKovMBx2pjT5OV9O9IS1NAvhl5B9R1qXzhsA6Z6VlW8zYyccd6u2UwumaxtrCW61GU7omR8BVHLcDrS6jasevR3e5I4ol2ktlmboKcVEisWwTnsM5rN8swqcLy3f2q5G/CAMcD8q9p6nAed/E3wRHeO+o6Sh+24BaNOFf/AOvXltpcy28pjkBVkba6kcgjsa+m2kVl8suu7sAOlcd4l8G2GsytM0JWfGTNF8rj6+o+tclWhfVGsKjWh5xa3SyLx2q7HKCo+Yg+mafqPgjVtLhN1Zj+0rUZy0C4dR7r3/Csq2mWZSUbLA8qeCp9x1FcsoOOjNlO5srOQwHGO/NPMu4nsKzlbA+brTg7BTzwe4pWHc0vMxjaQW96TzX7gcdcVUWQY7j+dLvJ6Y49aLBcuCYjG4EAU7zl28MRiqIY5yzYPpUisOQTgUagWo24wpJJHcU9S4HJJ557VVRyoyPwpQ+SDgmkVct+aQSOnHpQJOBz8x/Gq/mA8cD3z1pY5AW2gc+uaECLyMfcetWQyp8wJ4/OswMQ+R1HpTxIQQc9eoIoGmaXnEKSScVELouuASv9aqGXJ696YXJYgnOf1poLlhrsE7dxYfSo/NG7B9OnrVWQ5OU+XHYU7jHXc3v2phcsKVzkDr705ZAQB0H0qupAGVBIxTWkIXoB7d6LCuTSsQc5BX096heRsYJI/Gm+aW5J57ZFQEkZJNFhXHs/I5yBycU5H3dCMH1OBUTZ7DIPfFORCi+o+tFguTLt5OevQimtIsb4Y5Pt0pg3YGBk01+QASMH3osFyRpjzjIyKgkfJySP60rDA4wAPU1Cw5C4yTz607CuMJLHHf3puPXPB7VIEO3BJzS7cgDPNSC8xqjAzu59PSlGBgknPoBSsMHJPJ6DFReYwOB1z2FBRKW684NRDK5OPx6VG+T8x4IpkkhxznPTihIaJozgH5jnrSlyOWb9arrLtXGOPaoJJeoz+FFiWyzJL1GMn1qEzbQM8CqrykZz2q74X0LVPFeqfYtJTCLzNcSf6uFfU+/tU2b0Q7pasm0qC71nU4NO0qBprqY4AA4Uf3iewFe5eHNHsfBNg0Nq3n6rNjz7pgG3Y7L6LUOh6fpvhCwNjoeJriQAXF0fvzN/Qe1VdRv0swJL2Xy5j/yyH3z7/Su6hh1D3pbnNUqc2i2LOqQOY18vbtz94HoPrVB5FiVUZ8EHO3196pJrIuIwZHcYACqMY/KpUmSXLiRGz95iMYrqZii7BOJHZkJO4EDHX61LDceZbMqqEBGw5PzfjWXubyxKGWOIcHaetRW86jH31Q9Rnr70mM1QH091mtOEPVGP3vf2qLU/CeheLkM7Rm01FRxND8kmf5H8aIbpZk8oYwT1NTGRoLrzY2ZW7cY4HeocUVc8v8V+F9e8K7pbi3bUdOB/4+IY/nQf7Sj+lYVrqNtdLugkVvbP86+krLVY7q2FtqTBd/CtxhvQH0NcJ42+F+k6rJLc2sbWV2ORLD8mT6EdDWEqPWJan3PMQ4PQfl1qRXBqjq3hvxJ4cZgyJqECnrGMPj6Vn23iG33bblZIHHB8xduDWLi0XzJnRjDIA+Tg08ruIK5wKqWd7BcKfKkjcEdiK0I0+X7vHXiixVxmzd0zxTyQq9DipgmRnocdKeYR759hS5R3Kq7ivGfxFOVOdzEZ7AdasrHzjnntipVhLdAQfftRyhcr7sEdcGm5Ytk8A9BirflHpkbjS+QeMg+xHFHLcLlXkDjkdyKQFsfeyD2qy0RyAVzSiLgcCnyhcrjt0+gx+tLkA/cxVgRcHdyPTFOSNQ2SF57nrRYLlHaWkIXH1I/lTgh68e+BVuVG7LkHsTigxMcZyB6Z4p2C5ScM2AwBHYAdaYQ2QqxgDuTV7yCeR+goEBL4bjFKwJlFRyA2cDpxT9hyPlwD61akjA69c02QEgbRz2osBXZSuQveoeecDgdcVa8tmPKGmtE2MY6dqGHqVigAz+dMz124A9KsiFyTu5FMeLCnA6+lTYZAUJOVyR35pRx2z+NPZTjJJz0wKaI8LgE8+1KwEEhxz1b1qLDYGeT9Ks+S27jqad5Bxzninyhcz5ARz83PrTTnAJHTv2rQ+ys3AGRSHT3OSAQAO/FPlC5nSOSBgVUmJVSWO0dye1allaXep3ps9It2vLjOGMf3U92boK9K8L/Diz06WO+8QSDULtfmS2XiKM+/978aqNNydkS5KJwvgzwNf+JXW5uGfT9HBy1w6/NKPRB3+tewWcFnpGljTtCjW0sk++x6sf7zHuTVq8mEygFXAUYVUOFH+FZFxHNcYEr4A4CqK6qdKNNeZjKbluUbzVZEZ47TY79DIV4PuKyorGW7lMkrsXPUk/41urY7QSVU/TrUdy5gjOcIvpnmtHK25mzz4o4bMbGMdsHk1Yj1G4iX94olGMfhVa1vYbkhQwVz1Q9/xq75BYbQuOOOaCSaPW7cSIsu5fTK/KK04r2KdMxyI/pzWAbANkqu7/aqFrFkORkHOeKVxnYQyFUxjGateaZPmYbiFwTzXFK17FGgjuZFx0JOcVZj1u8hUpcRrNzyQdpxRcdzrFmLuIzwv8WDjitay10wJFb3LvInRHck49ia5S01qyn2qXaBv+mg4/OtNYH8jeCGjYZyDnIo2GdRcpDfR4kxx8wwOB+NcZ4g8KWeoMXESK6jglRyPer9tNcWxAYFoh/CTz+FaUdysipzkAcjHIpNJhc8sbwPZMHLReTKvKunGaqSeFtQtSXtNQnCg/3s/wA69XdVlc71ye3AAB96zngZH2t0zk4rNwRSkebKmvQj78c4/wCmkYNTR6pqcQAl0+CTHXaSpr0GO2jZ87QPX61YTSoJOqc+tT7MrmZ59Hryqf8ASNNuE/3HBqZfEWm9JFuos+sWa71/DVtJ0Mak/jVK98IWUUZknmiQerHFL2bDnOXi1rSJDgXmwn+/GRV2K5tJgPKuonPYg0+XQ9DRt0t/BtHZeTUi3Wg6YoW1ie5f6YFNU2PnGKLdmOLiAn/acCpPsxZcs8KqenzcGsu/195SRDa20KeuwE/nWDdXLykl2Jo9kHOdibNDgtJHtHGdwpRZoeDJEB2O4V57cFn4OcelUpLdic8k+ualxGpnqAtE6+ZEeOMuKT7JHknzIh/wMf415WLWQjBZuPQ1Its2AGZyB7mpsVc9Q+zpjiWNh3O8U1oEJK+bDz0G8V5wkLLt5J/GnpF3yR70WDmPRRZgjh489zkUpslAGWQH0BFee88Hc3HTmkZ3J++350WDmPQvsygEbkHPXdTDaR5B3oxPUMwrz12fB+c4+tQuzH+JsfWnYOY9Fltlwf3iL/wIVD9mgUfNcQgdyXFeeYc7cs3500xE9z+dKyC53zvYI3z31sPYNmoZL3SkBH2nc3fYpNcZBbYIzitCK39RTSuS5HQf2jYqo8qKZ/fGKaNRjzmO1Uf7zZzWZHEARkHFShc4J/KrUEZym+hc/tCU9FjQeirU32qwn5vrLzcdhIyg/hWaoyeOlKqk/dqrIz5pdzsdP8axaVbLb6RpFtbRD7wH8VJN47vXkc/ZIQnZcniuUWBi3Tmh4yvGDmm5O2grs6Wbx9ehf3dlbg46sSazX8c6q9yrTCLyc8xxrj9axHTJ5GagkjJ4APvWUpSFdnf2viLT71FaS8MbnqjnGPxrZhihdVkfEkR7jn8q8ieByOnHv3rW0LUZ7MeS8siRH7pB4X2rFvuF+5xMl5egDAhz2IJrY0XxRPbMseopvjxjev3h/jWMeoqB+tdqlqUerWGoQXsQe0mWQdx3H1FWgHPXb7eleSae7R3MZjZkO7qpxXrdgSQuSTwP5Ve6AT7KXGTtHFJ9gyMkHFaFv/q1PfNWU53Z9aLBYxv7K3jIQjPTNWotPni2eTI0ZUfe3cCrjM3mgZOPTNNBJk5JPPeiwyVZ7lU2mVZef4hVuykkcgvbjI/iDdKroB8vAq7MSLc4OPl7UDG3d/awEq6Mx/iK0yK/spEJdZUQdSw6fjWS4yBnnmsvxS7KkSBiFPUA8UgudC2t6IPlWabIPXZnNK3iHT40HkR3En1+WuJtQCRwO1aCD5h9KQJmrd+Jr1gRaokC+o5b8656/vp7tg1zK8hHqadc/eP0qk/f60wA5A4H50hU44FTRgZHHapIQDjPPNK4FQQlhgAnNOGmyuPlQ11WlxpsX5F/KtXYgU4VRz6VI0efNpUg/hqB9OkB+4cV6DMi7vuj8qpSIuT8q/lSsUjhXsXU5K0w2smTgcV2ciL83yjr6VCUTn5V6elTylXOSNq4/hpfsr8cGup2Lx8q/lUgRNv3V/KlYLnJ/Z3wflOemKjNpJn7prsNi7h8q9PSl2JgfKvX0otcLnGGzlPAQ4+lNGnTsfuHFdzCic/Kv5VYSNOPkX8qOVBc4NdJmJ+4c1YTRZSc7Dj6V3yRptPyL09KshFx91enpT5EJs4WLRpdo+U47VaTSJB1XJx0rtY0XH3R09KkRFx90flVcpLOLXSZG6g1ImiSHgqc128aLuHyj8quxImT8q/lTsTY4iDw+5HINX4PDZJyV4967eJF2j5V6elW7dV9B+VNRJscV/YARcbB+FUrjRcdFr0W4VQnCj8qy5lX0H5U3FBY4BtD3H7tTR+HsjJQn8K7eFFLnKr+VWURcr8o/Ko5EKxw6+HVI5QZ+lU7nQlVCNvIPpXpEiqCcKOnpWRqKjjgUciFY//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A salmon-pink rash is characteristic of this JIA subtype. The rash is brought out by heat and often can be found in the axillae and around the waist, but may be present anywhere on the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Sundel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_24_13711=[""].join("\n");
var outline_f13_24_13711=null;
